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Gastric cancer (GC) and colorectal cancer (CRC) are two of the top ten cancers 
and leading causes of death worldwide, and in Singapore. Inhibition of the 
phosphatidylinositol-3-kinase (PI3K) signalling pathway is a cancer treatment 
strategy that has entered into clinical trials for GC and CRC patients. Based on 
previous experience in targeted therapy development, ethnic differences, co-
occurrence pattern of pathway aberrations and predictive biomarkers are 
important in determining the success of drug therapy. The aims of this study were 
1) to characterise inter-ethnic frequencies and co-occurrence patterns of 
prominent PI3K pathway aberrations in GC and CRC, and 2) to identify 
predictive biomarkers for PI3K inhibitors in GC and CRC cells. 
A meta-analysis was first performed on the frequency of genetic (PIK3CA 
mutation, PIK3CA amplification, PTEN deletion) and protein expression (high 
PI3K, PTEN loss, high pAkt) aberrations in the PI3K pathway in GC and CRC. 
Sanger sequencing, quantitative PCR (qPCR) and immunohistochemistry were 
also performed to investigate the co-occurrence of these aberrations. OncoCarta 
analysis and RNA-sequencing were used to identify potential predictive 
biomarkers for PI3K inhibitors. In-vitro manipulations and interrogations were 
performed to investigate the role of candidates in determining PI3K inhibitor 
sensitivity. 
The meta-analysis indicated that East Asian and Caucasian GC patients 
differ significantly in the frequencies of PIK3CA exon 9 and exon 20 mutations 
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(7% vs. 15% respectively), PTEN deletion (21% vs. 4%) and PTEN loss (47% vs 
78%), while CRC patients differed for PTEN loss (57% vs. 26%). High study 
heterogeneity (I
2
>80) was observed for all aberrations except PIK3CA mutations. 
Analysis of tumours from East Asian patients revealed significant differences 
between GC (n=79) and CRC (n=116) for the frequencies of PIK3CA 
amplification (46% vs. 4%) and PTEN loss (54% vs. 78%). The incidence of GC 
cases with 0, 1, 2 and 3 concurrent aberrations was 14%, 52%, 27% and 8% 
respectively, while for CRC it was 10%, 60%, 25% and 4% respectively. 
OncoCarta analysis revealed that PIK3CA mutation (p=0.001) was associated 
with increased sensitivity to PI3K inhibitors, and KRAS (G12V) mutation 
(p=0.004) was associated with decreased sensitivity to PI3K inhibitor in CRC cell 
lines. To identify biomarkers for PIK3CA wildtype cell lines, RNA-sequencing 
was performed and high expression of IGFBP3 was identified as a top candidate 
associated with increased sensitivity to PI3K inhibitors. siRNA experiments 
confirmed the role of IGFBP3 in mediating sensitivity to PI3K inhibition.  
In conclusion, this study consolidates knowledge on the frequency, co-
occurrence and clinical relevance of PI3K pathway aberrations in GC and CRC. 
Up to 86% of GC and 90% of CRC have at least one aberration in the PI3K 
pathway, and there are significant differences in the frequencies of these 
aberrations according to cancer type and ethnicity. Moreover, this study has 
helped to reveal novel candidate biomarkers for GC and CRC that could assist in 
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1.1 Gastric cancer 
Gastric cancer (GC) is the third leading cause of cancer death in the world 
(GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence 
Worldwide in 2012). Almost one million new cases of GC were estimated to have 
occurred in 2012 (952,000 cases, 6.8% of the total), making it the fifth most 
common malignancy in the world, after cancers of the lung, breast, colorectum 
and prostate. More than 70% of cases (677,000 cases) occur in developing 
countries (456,000 in men, 221,000 in women), and half the world total occurs in 
Eastern Asia (mainly in China). In Singapore, between 2009 to 2013, GC was the 
fourth most common cause of cancer death in men (913, 6.7% of the total) and the 
fifth most common cause of cancer death in women (690, 6.1% of the total) 
(Singapore Cancer Registry Interim Annual Registry Report Trends in Cancer 
Incidence in Singapore 2009-2013). It is estimated that there will be 22,200 new 
cases in the U.S. in 2014 and 10,990 GC-related deaths in the same year (SEER 
Stat Fact Sheets: Stomach Cancer).  
The majority of GCs are adenocarcinomas which can be divided 
histologically into an intestinal or diffuse type and anatomically into cardia or 
noncardia cancers. Pathogenesis and prognosis differ based on GC subtype. 
Intestinal-type GC, for example, is more common in Asia and tends to be 
associated with Helicobacter pylori (H.pylori) infection (Yakirevich and Resnick, 
2013). H.pylori, which colonizes the human stomach, is the strongest known risk 
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factor for gastric malignancies, in particular non-cardia gastric adenocarcinoma 
(cancer in all areas of the stomach, except for the top portion where it joins the 
oesophagus) and mucosa-associated lymphoid tissue lymphoma (Israel and Peek, 
2010). It is also estimated that H.pylori accounts for ∼80% of non-cardia GC 
which is potentially preventable (Helicobacter and Cancer Collaborative, 2001). 
Epstein–Barr virus (EBV) is a herpes virus that infects most humans in 
adulthood. EBV is associated with several human malignancies, such as Burkitt’s 
lymphoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma and GC. In 1990, 
EBV genomes were detected in GCs using polymerase chain reaction (Burke et 
al., 1990) and in situ hybridization (ISH) for EBV-encoded small ribonucleic acid 
1 (EBER1) (Liu et al., 1995). It is estimated that EBV-associated gastric cancer 
comprises about 1.3–20.7% of all GCs worldwide (Shibata and Weiss, 1992; 
Hsieh et al., 1998; Morewaya et al., 2004). A characteristic feature of EBV-
associated gastric cancer is lymphoepithelioma-like carcinoma, which presents as 
diffuse-type histology with lymphoid infiltration. Diffuse-type GC seems to have 
a worse prognosis (Miyahara et al., 2007; Yamashita et al., 2009).  
Currently, there is no optimal treatment for advanced GC. In order to 
improve outcomes, it is critical to understand the molecular pathogenesis of GC 
(Wong and Yau, 2012) and to identify biomarkers of prognostic or predictive 
significance. Ideally, physicians will be able to tailor therapy toward individual 
patients according to biomarkers suggesting increased likelihood of response, thus 
improving outcomes for those with GC and sparing patients without these 
predictive biomarkers from the toxicities of ineffective therapies. 
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1.2 Colorectal Cancer 
Colorectal cancer (CRC) is now the third most common malignant disease in both 
men and women in Asia. In the Asia-Pacific region, the incidence varies between 
regions, with high incidence in Australia and Eastern Asia. GLOBOCAN 
estimation project for 2012 indicated that, the age-specific rates (ASR) incidence 
for Asia was 13.7 and ASR mortality was 7.2 per 100,000 (GLOBOCAN 2012: 
Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012). 
Although the incidence and mortality rates of this cancer are still higher in the 
western world, the ratio of mortality/incidence for Asian regions are higher, 
indicating poorer survival in Asian countries.  
CRC is a heterogeneous disease with three different, but partly 
overlapping, molecular phenotypes reflecting different forms of DNA instability. 
The chromosomal instability pathway (CIN) is the most common phenotype, 
accounting for ~85% of all sporadic CRCs (Lengauer et al., 1997; Hermsen et al., 
2002; Nowak et al., 2002). The malignant cells in CIN tumors are typically 
aneuploid and reveal large-scale chromosomal rearrangements. The microsatellite 
instability (MSI) phenotype represents ~15% of all CRCs and is caused by 
various deficiencies in the DNA mismatch-repair system, leading to a large 
increase in the mutation rate (Shibata et al., 1994; Lothe, 1997). Cancers with the 
CpG island methylator phenotype (CIMP) exhibit aberrant DNA methylation, 
leading to concordant promoter hypermethylation of multiple genes (Issa, 2004).  
Despite the established relationship between H.pylori and GC, the 
association between H.pylori and CRC is much less clear. Using PCR, one study 
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found that 1.2% of malignant colorectal tissues were positive for H.pylori, 
whereas 6.0% of normal tissues were positive (Bulajic et al., 2007). Therefore, 
the authors concluded that H.pylori are not important in the pathogenesis of CRC. 
However, two other studies that used PCR to detect H.pylori in colorectal 
neoplasms indicated that a much greater proportion of these tissues were positive 
for H.pylori: one study detected H.pylori DNA in 27% of colorectal 
adenocarcinoma tissues (Grahn et al., 2005) and another found that detection of 
H.pylori DNA in colorectal tissue was associated with an increased risk of 
colorectal adenocarcinomas (Jones et al., 2007).  
 
1.3 Molecular aberrations and targeted therapies in GC and CRC 
Although surgery and cytotoxic chemotherapy are the main treatment modalities 
for GC and CRC, drug resistance and lack of specificity are major problems. The 
past two decades have seen some progress towards the development of “targeted 
therapies”. These therapies are designed to exploit the dependency, or 
“addiction”, of cancer cells on specific signaling pathways or oncogenes. By 
specifically inhibiting the pathways on which tumour cells are dependent for 
survival, normal tissues may thus be spared. This should be associated with less 
side effects and better overall better drug efficacy (Zhukov and Tjulandin, 2008).  
 A number of molecularly targeted drugs have been developed as a 
consequence of improved understanding of the molecular aberration in GC and 
CRC (Figure 1.1). For instance, epidermal growth factor receptor 2 (HER2) 
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amplification or overexpression is observed in 10-38% (Wong and Yau, 2013) of 
GC tumour samples and HER2 inhibitors have been developed for GC treatment 
such as trastuzumab and pertuzumab (Yamashita-Kashima et al., 2011). In the 
clinic, the combination of trastuzumab and chemotherapy is the standard of care 
in first line therapy for HER2 positive GC patients (De Vita et al., 2012). 
Overexpression of epidermal growth factor receptor (EGFR) has also been 
observed in GC and CRC (Spano et al., 2005; Galizia et al., 2007). Inhibitors that 
target EGFR (cetuximab and panitumumab) have been approved for the treatment 
of metastatic colorectal cancer (Bartlett and Chu, 2012). However, EGFR 
inhibitors are still in clinical trials for GC treatment (Wong and Yau, 2013). 
 Amplification of met proto-oncogene (MET) and fibroblast growth factor 
receptor 2 (FGFR2), mutation of v-raf murine sarcoma viral oncogene homolog B 
(BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) have also been 
reported in GC and CRC (Di Nicolantonio et al., 2010; Deng et al., 2012). 
Several inhibitors that target MET, FGFR and BRAF are being studied in clinical 
trials or are in preclinical testing (Mao et al., 2013; Wong and Yau, 2013). 
Moreover, therapeutics targeting the phosphoinositide 3-kinase (PI3K) pathway 
are being developed rapidly due to the fact that PI3K is a major downstream 
effector of receptor tyrosine kinases (RTKs), and the PI3K pathway is activated in 




Figure 1.1. Schematic diagram of molecular aberrations and targeted 
therapies in GC and CRC (Wong and Yau, 2013).  
 
1.1 The phosphoinositide 3-kinase family: structure and function 
PI3K is a lipid kinase that phosphorylates phosphatidylinositol (4,5)-biphosphate 
(PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3) (Chalhoub and Baker, 
2009). PI3Ks are subdivided into four different classes based on their subunit 
composition and the substrate specificity for phosphoinositides (Vanhaesebroeck 
et al., 2001). Class I PI3Ks are further divided into IA and IB on the basis of their 
mechanism of activation (Stein and Waterfield, 2000).  
The class IA group forms a heterodimeric complex consisting of a 110 
kDa catalytic subunit and a regulatory subunit. The three catalytic subunits 
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(p110, p110β, p110δ) are encoded by PIK3CA, PIK3CB and PIK3CD, 
respectively. p110α and p110β isoforms are ubiquitously expressed among 
tissues, whereas p110δ is more restricted to hematopoietic cells (Bader et al., 
2005). All class IA PI3Ks contain an N-terminal adaptor binding domain (ABD) 
followed by a Ras-binding domain (RBD), a C2 domain, a helical domain and a 
catalytic kinase domain. There are five isoforms of the regulatory subunits of 
class IA PI3Ks: p85α, p85β, p55γ, p55α and p50α (Foukas and Shepherd, 2004).  
Class IB PI3K proteins consist of a catalytic subunit, p110 (encoded by 
PIK3CG) and a regulatory subunit of which p101 is the most common. Its 
expression is largely confined to leukocytes (Foukas and Shepherd, 2004). The 
p110γ subunit is activated by G-protein βγ subunit following stimulation of G-
protein coupled receptors (Walker et al., 2000; Shepherd, 2005). 
Class II kinase is a large protein (170-210 kDa) characterised by the 
presence of an N-terminal RBD, a C2 domain, a helical domain, a catalytic 
domain, a PX domain and a C-terminal C2 domain (Katso et al., 2001). There are 
three isoforms in mammals and these are products of separate genes: PI3K-C2 , 
ß and . No regulatory subunits have been identified to date.  
The biological function of class III PI3Ks is less well established, although 
it is thought they can be activated by RTKs such as EGFR and insulin receptor 
(IR). Moreover, they play an important role in clathrin-mediated vessel trafficking 





Figure 1.2. Substrate specificity and domain structure of different classes of 
PI3Ks (Zhang et al., 2011).  
 
1.2 RAS/RAF/MEK  and PI3K/AKT signalling pathways 
RAS is activated in human cancer by a number of different mechanisms, such as 
mutations in RAS, loss of GTPase-activating protein (GAP) or overexpression of 
RTKs (Downward, 2003). RAS protein signals through direct interaction with a 
number of effector enzymes. RAS/RAF/MEK pathway was the first RAS-effector 
pathway identified. RAS fluctuates between an inactive guanosine-5’-diphosphate 
(GDP)-bound state and an active guanosine-5’-triphosphate (GTP)-bound state 
(McCubrey et al., 2007). The RAF family of proteins (Raf-1, A-Raf and B-Raf) 
are serine/threonine kinases that bind to the effector region of RAS-GTP, thus 
inducing translocation of the protein to the plasma membrane. RAF proteins are 
phosphorylated by protein kinases such as protein kinase C (PKC) and bind to 14-
3-3 proteins (Fabian et al., 1994; Morrison, 1994; Marais et al., 1995; Avruch et 
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al., 2001). Active RAF phosphorylates MEK which in turn phosphorylates 
extracellular signal regulated kinases 1 and 2 (ERK1/2) (Crews and Erikson, 
1993). ERK phosphorylation promotes homodimerization and translocation of 
ERK to the nucleus, where they stimulate the activity of different transcription 
factors, such as p62/Elk-1 and Ets-2 (Marais et al., 1993; Treisman, 1996; 
Khokhlatchev et al., 1998). 
PI3K is another well-characterized downstream effector of RAS. PI3K can 
also be activated by RTKs. A model for PI3K signalling is shown in Figure 1.3. 
Binding of ligands such as insulin, platelet derived growth factor (PDGF) and 
epidermal growth factor (EGF) to RTKs initiates the dimerization of RTKs which 
then leads to their auto-phosphorylation at tyrosine residues. This allows them to 
activate class IA PI3K through interaction with the SH2 domain in the regulatory 
subunit (Cully et al., 2006). Apart from membrane-bound receptors, substrates of 
RTKs such as insulin receptor substrate (IRS) and GRB2-associated binding 
protein 1/ GRB2-associated binding protein 2 (GAB1/GAB2) can lead to 
activation of PI3K. Moreover, class I PI3Ks can be activated by direct binding of 
p110 to activated RAS, allowing its localization to the membrane and activation 
of its lipid kinase activity (Rodriguez-Viciana et al., 1994; Katso et al., 2001). 
Activated PI3K transduces signals by generating intracellular PIP3 second 
messenger. The tumour suppressor, phosphatase and tensin homolog (PTEN),  
antagonises this reaction by dephosphorylating the 3’ position of PIP3 (Cully et 
al., 2006). PIP3 signals are largely localized to the inner leaflet of the plasma 
membrane (Shepherd, 2005). This allows recruitment of signalling proteins with 
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pleckstrin-homology (PH) domains to the membrane by directly binding to PIP3, 
including serine/threonine kinases 3-phosphoinositide-dependent kinase 1 (PDK1) 
and v-AKT murine thymoma viral oncogene homolog (AKT), also known as 
protein kinase B (PKB) (Meili et al., 1999). Subsequently, AKT is 
phosphorylated at two sites, Thr308 and Ser473 by PDK1 and mammalian target 
of rapamycin mTOR complex 2 (mTORC2) respectively (Sarbassov et al., 2005). 
Phosphorylation of both Thr308 and Ser473 is required for full activation of AKT 
(Andjelkovic et al., 1997). The biological function of AKT became apparent 
when it was revealed to be a major downstream effector of the PI3K pathway. 
AKT activates a wide range of substrates to mediate cell proliferation, growth, 
metabolism, survival and angiogenesis (Stauffer et al., 2005). For instance, 
phosphorylation of glycogen synthase kinase-3 (GSK3) leads to the 
phosphorylation of transcription factors such as v-myc myelocytomatosis viral 
oncogene homolog (Myc) and jun (Jun) oncogenes, as well as the cell cycle 
regulators cyclin D and p21 (de Groot et al., 1993; Nikolakaki et al., 1993; Sears 
et al., 2000; Rossig et al., 2002; Gregory et al., 2003; Wei et al., 2005). Activated 
AKT also phosphorylates tuberous sclerosis 2 (TSC2) at multiple sites, which in 
turn relieves the inhibitory effects of the TSC1/TSC2 complex on Ras homolog 
enriched in brain (Rheb), thereby activating mTORC1 in response to growth 
factors (Kovacina et al., 2003). mTORC1 stimulates protein synthesis by 
phosphorylating proteins such as p70S6 kinase (p70S6K) and eukaryotic 
translational initiation factor binding proteins 1 (4E-BP1) (Ruggero and Pandolfi, 




Activated AKT also suppresses apoptosis via the regulation of forkhead box O 
transcription factor (FOXO) or BCL-2 antagonist of death (BAD). Phosphorylated 
FOXO forms a complex with the 14-3-3 family of proteins in the cytosol, which 
in turns inhibits the transcription of anti-apoptotic genes such as p27 and p21 
(Cardone et al., 1998). AKT negatively regulates the pro-apoptotic protein BAD 
by generating binding sites for 14-3-3 proteins. This prevents BAD from 
interacting with B-cell CLL/lymphoma 2 (BCL2) family members and allows 





Figure 1.3. Model for regulation of the PI3K/AKT signalling pathway. 
Upstream activation of PI3K by RTK or GPCR leads to activation of PI3K, 
resulting in generation of PIP3. Membrane bound PIP3 recruits AKT and PDK1, 
which in turn leads to activation of AKT and its downstream effectors (Zhang et 




1.3 PI3K pathway aberrations in human cancer 
Deregulation of the PI3K/AKT pathway has been directly implicated in several 
human cancers (Samuels and Velculescu, 2004). In 2004, Samuels et al. 
sequenced the kinase domains of eight PI3K genes in 35 primary colorectal 
carcinomas and found that only PIK3CA, the gene encoding p110, harboured 
somatic mutations. Full exon sequencing of PIK3CA in an additional 199 CRC 
showed that most of the mutations were predominantly located within the kinase 
and helical domains (Samuels et al., 2004). Three hot spot mutations occur within 
the kinase and helical domains: E542K, E545K and H1047R. Further 
investigation of PIK3CA mutation in additional tumour types reveals this gene is 
mutated in approximately 15% of human cancers (Karakas et al., 2006). 
Expression of PIK3CA containing the hot spot mutations in chicken embryo 
fibroblasts induced oncogenic transformation and elevated lipid kinase activity 
(Samuels and Velculescu, 2004; Kang et al., 2005). Several studies have reported 
that PIK3CA mutations found in human cancer increase the lipid kinase activity of 
PI3K by several fold.  
Transformed cells with PIK3CA hot spot mutations are also tumourigenic 
in animal models. For example, transgenic expression of the H1047R mutation 
induces lung adenocarcinoma (Engelman et al., 2008). Moreover, Gymnopolous 
et al. (2007) showed that 14 out of 15 rarer PIK3CA mutations found in human 
cancers were gain of function mutations. However, these rarer mutations were 
associated with lower levels of lipid kinase activity than the three hot spot 
mutations. Figure 1.4 summarizes the various PIK3CA mutations that have been 
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reported in studies to date. Although all the three hot spot mutations are gain of 
function mutations, the activity of helical domain mutations (E542K and E545K) 
are dependent on Ras activation but independent of binding to p85. In contrast, 
the activity of the kinase domain hot spot mutation (H1047R) is highly dependent 
on the interaction with p85 but independent of RAS-GTP binding (Zhao and 
Vogt, 2008). 
Mutations in PIK3R1 coding for p85 have been identified in ovarian and 
colon tumours (Philp et al., 2001). Several PIK3R1 mutations in the inter-SH2 
(iSH2) domain have been shown to enhance the PI3K signaling pathway through 
activation of AKT, leading to stimulation of cell replication and oncogenic 
transformation (Jaiswal et al., 2009). Mutations in the iSH2 domain disrupt the 
inhibitory contact of p85α with p110 (Jaiswal et al., 2009; Wu et al., 2009). 
 
Figure 1.4. Gain of function mutations in PIK3CA (coding for p110) and 
PIK3R1 (coding for p85). The three hot spot mutations are in red, rarer 
mutations in blue and engineered gain of function mutations are marked by an 
asterisk (Christian Rommel, 2011). 
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Although few cancer-specific mutations have been observed in other 
isoforms of class I PI3Ks, differential expression of other isoforms has been 
reported in human cancers (Benistant et al., 2000; Jiang et al.). Wildtype non-α 
isoforms have the ability to induce oncogenic transformation when overexpressed 
in cell culture, whereas wildtype p110α lacks this ability (Kang et al., 2006). This 
suggests the oncogenic potential of non-α isoforms may correlate with their 
expression levels. 
Aberrations of upstream or downstream effectors of the PI3K pathway 
have been reported in human cancers. For example, the mutation, amplification 
and overexpression of EGFR and HER2 occur in breast, lung and gastric cancer 
(Press et al., 1997; Selvaggi et al., 2004; Tanner et al., 2005). PTEN is also 
frequently mutated in various tumours including prostate cancer, glioblastoma, 
melanoma and endometrial carcinoma (Kang et al., 2005). PTEN is also 
frequently inactivated by other mechanisms, including gene deletion, targeting by 
micro-RNA, promoter methylation and phosphorylation (Keniry and Parsons, 
2008; Salmena et al., 2008). Several human tumour types including ovarian, 
pancreatic, breast and gastric cancers show amplification of AKT1 or AKT2. A 
transforming mutation in the PH domain of AKT1 (E17K) resulting in constitutive 
activation is observed in a small percentage of breast, colorectal, ovarian and 
bladder cancers (Carpten et al., 2007; Askham et al.). However, this mutation was 
not found in gastric cancers from Korean and Japanese populations (Kim et al., 
2008; Li et al., 2008). Elevated AKT phosphorylation in cancer has been 
15 
 
associated with activation of PIK3CA and inactivation of PTEN in some (Li et al., 
2005; Oki et al., 2005) but not all studies (Vasudevan et al., 2009). 
 
1.4 PI3K inhibitors 
The high frequency of PI3K pathway aberrations and the discovery of PIK3CA 
hotspot mutations have made PI3K an attractive target for anti-cancer drug 
development. A number of PI3K inhibitors have been developed and are now 
undergoing clinical trials (Table 1.1). Most of the protein kinase inhibitors that are 
now in clinical development are directed against the ATP-binding site of PI3K 
(Dancey and Sausville, 2003) and only a few allosteric protein kinase inhibitors 
exist (Walker et al., 1999; Parang and Sun, 2004). Despite similarities in ATP-
binding site amongst closely related protein kinases, the development of specific 
kinase inhibitors has been successful and these pharmacological inhibitors have 
also been instrumental in delineating signal transduction pathways. 
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Table 1.1. PI3K inhibitors in preclinical studies and in clinical trials.  
Company Target(s) Status Cancer Types Drug 
Pan-PI3K inhibitors     
Lilly PI3K, other kinases Preclinical NA LY294002 
Wyeth/Pfizer PI3K Preclinical NA PWT-458 
Zenyaku Kogyo Co. Ltd PI3K Phase I Advanced solid tumours ZSTK474 
Oncothyreon Inc. PI3K Phase I Advanced solid tumours, CRC, melanoma, Prostate, NSCLC, SCCHN, GBM PX-866 
Exelixis/Sanofi-Aventis PI3K Phase I Advanced solid tumours, GBM, lymphoma, endometrial, ovarian, breast, 
NSCLC 
XL-147/ SAR245408 
GlaxoSmithKline PI3K Phase I Terminated GSK615/ 
GSK1059615 
Chugai Pharma Europe Ltd PI3K Phase I Advanced solid tumours CH5132799 
PIramedPharma/Roche/ Genentech PI3K Phase I Advanced solid tumours, breast, NSCLC, non-Hodgkin’s lymphoma GDC-0941 
Bayer PI3K Phase I, II Neoplasm, NHLs BAY 80-6946 
Novartis PI3K Phase I, II Advanced solid tumours, NSCLC, endometrial, prostate, breast, colorectal, 
pancreatic, RCC, GIST, melanoma, GBM, leukemia, SCCHN, TCC 
NVP-BKM120 
PI3K-mTOR inhibitors     
NA PI3K, mTOR, DNA-PK, MAPK Preclinical NA Wortmannin 
PIramedPharma/Roche PI3K, mTOR, DNA-PK Preclinical NA PI-103 
Semafore PI3K, mTOR Phase I Advanced solid tumours SF1126 
Novartis PI3K, mTOR Phase I  Advanced solid tumours, breast NVP-BGT226 
Novartis PI3K, mTOR Phase I, II Advanced solid tumours, breast, renal cell, endometrial, pNET, prostate, breast NVP-BEZ235 
Exelixis/Sanofi-Aventis PI3K, mTOR Phase I Breast, GBM, astrocytoma, NSCLC XL765/ SAR254409 
Roche/Genentech PI3K, mTOR Phase I Advanced solid tumours, NHLs, breast, prostate, endometrial, RCC GDC-0980 
GlaxoSmithKline PI3K, mTOR, DNA-PK Phase I Terminated GSK1059615 
Pfizer PI3K, mTOR Phase I Advanced solid tumours, endometrial PKI-587/PF-05212384 
Pfizer PI3K, mTOR Phase I Advanced solid tumours, endometrial, breast 
 
PF-04691502 
Isoform-specific PI3K-I inhibitors     
Alexis/Enzo Life Sciences Inc. p110β Preclinical NA TGX-221 
Novartis p110α Phase I Advanced solid tumours, SCCHN, GIST, CRC, GC, esophageal, breast BYL719* 
Intellikine/MillenuimPharmaceuticas p110α Phase I Advanced solid tumours MLN1117 
Genentech p110α Phase I Advanced hormone receptor-positive breast cancer GDC-0032 
GlaxoSmithKline p110β Phase I Advanced solid cancers  GSK2636771 ** 
Calistoga Pharmaceuticals p110δ I, II, and III CLL, Hodgkin lymphoma, NHLs,MCL, AML, multiple myeloma CAL-101 
CRC: colorectal cancer; GC: gastric cancer; TCC: transitional cell carcinoma; NSCLC: non-small cell lung cancer; SCCHN: squamous cell carcinoma head and 
neck cancers; RCC: renal cell carcinoma; GBM: glioblastoma multiforme; NHLs: Non-Hodgkin lymphomas; CLL: chronic lymphocytic leukemia; MCL: mantle 
cell lymphoma; ALL: acute myeloid leukemia; pNET: pancreatic neuroendocrine tumours. *BYL719 has been administrated to patients whose tumours have an 
alteration of the PIK3CA mutation or amplification. **GSK2636771 has been be administrated to patients whose tumours have PTEN deficiency. 
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1.4.1 Wortmannin and LY294002 
Wortmannin and LY294002 were the first generation of PI3K inhibitors (Marion 
et al., 2006) and have served as probes for implicating PI3K in a wide range of 
physiological processes. The fungal metabolite wortmannin is an irreversible 
inhibitor that binds covalently to a conserved lysine residue in the ATP binding 
site of the p110 catalytic subunit. It inhibits PI3K at low nanomolar 
concentrations and is not specific to other lipid and protein kinases (Knight et al., 
2004). LY294002, a morpholino derivative of the broad-spectrum kinase inhibitor 
quercetin, is an ATP competitive inhibitor. LY294002 was also reported to inhibit 
casein kinase 2 with similar potency to PI3K (Davies et al., 2000). It is important 
to emphasise that neither wortmannin nor LY294002 displays selectivity towards 
a specific isoform within the PI3K family (Finan and Thomas, 2004). These two 
compounds induce strong G1 arrest in a variety of tumour cell lines, but the 
induction of programmed cell death is only observed in combination with 
standard anticancer agents or radiation (Stauffer et al., 2005). Due to the lack of 
selectivity of these compounds, the instability of wortmannin and the insolubility 
of LY294002, neither has shown therapeutic potential (Stokoe, 2005).   
 
1.4.2 pan-PI3K inhibitors 
Higher specificity pan-PI3K inhibitors have been developed, including GDC-
0941, NVP-BKM120, PX866, ZSTK474 and GSK1059615 (Table 1.1). GDC-
0941 is an ATP-competitive pan-class I PI3K inhibitors that inhibits 
phosphorylation of AKT and induces G1 arrest in cancer cell lines (Folkes et al., 
18 
 
2008; Raynaud et al., 2009). Currently, GDC-0941 is in Phase II clinical trials 
enrolling patients with advanced or metastatic breast cancer (NCT00960960). PX-
866 is an irreversible pan-class I PI3K inhibitor whose structure is based on 
wortmannin (Ihle et al., 2004). The primary metabolite of PX-866, 17-OH, is 
more potent than the parental compound in inhibiting p110α and p110β (Ihle et 
al., 2009). PX-866 has significant anti-tumour effects both in vitro and in vivo, as 
well as a more prolonged inhibition of PI3K relative to wortmannin (Ihle et al., 
2009). A phase II trial is evaluating the efficacy and safety to daily PX-866 in 
patients with relapsed glioblastoma multiforme tumours at first relapse as 
assessed by objective response and early progression rates (NCT01259869). 
 Recently, two Class I PI3K inhibitors (BSP-A and BSP-B) were generated 
by Bayer HealthCare. BSP-A is more specific in inhibiting p110α/δ, whereas 
BSP-B is more specific in inhibiting p110α/β. As these drugs are currently in 
development, access to more detailed information regarding both drugs is 
currently limited.  
 
1.4.3 PI3K-mTOR inhibitors 
NVP-BEZ235 is a dual PI3K/mTOR inhibitor developed by Norvartis Pharma 
AG. It was the first dual inhibitor to enter Phase I clinical trials for dose escalation 
in patients with advanced solid tumours (Maira et al., 2008; Schnell et al., 2008). 
At low nanomolar IC50 values, NVP-BEZ235 inhibits phosphorylation of AKT 
and the mTOR signaling pathway, and inhibits the proliferation of human cancer 
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cell lines (Maira et al., 2008; Serra et al., 2008; Cao et al., 2009; Liu et al., 2009; 
Marone et al., 2009). Moreover, NVP-BEZ235 acts synergistically with MEK 
inhibitors in lung cancers with KRAS mutation (Engelman et al., 2008).  Patients 
with advanced renal cell carcinoma are currently enrolled for Phase I/II clinical 
trials of NVP-BEZ235 (NCT01453595).  
SF1126 is another dual PI3K/mTOR inhibitor that consists of an RGDS-
conjugated LY294002 prodrug. It is designed to enhance efficacy through the 
binding of its conjugated peptide sequence to specific integrins on the surface of 
tumour cells (Garlich et al., 2008). SF1126 has favourable pharmacokinetics and 
inhibits cell proliferation in neuroblastoma, breast, glioma and prostate cancer 
cells (Garlich et al., 2008; Ozbay et al.). A phase I pharmacokinetic and 
pharmacodynamic dose escalation trial of SF1126 is tested in patients with 
advanced or metastatic tumours (NCT00907205).  
 
1.4.4 Isoform-specific PI3K-I inhibitors 
Many studies have focused on the roles of different PI3K isoforms in normal 
physiology. For example, transgenic knock-in studies were performed to 
investigate the role of p110α in insulin signalling while RNA interference was 
used to investigate the function of p110β (Kubo et al., 2005; Foukas et al., 2006). 
However, compensatory mechanisms arise because of the length of time the gene 
product is absent from the cell. The conclusions drawn from such experiments can 
therefore be somewhat ambiguous. This has led to the development of isoform-
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specific PI3K inhibitors with the aim of elucidating the physiological role of 
different PI3K isoforms in human cancers. This should be of interest clinically in 
terms of deciding which isoforms to target in diseases with different genetic 
contexts. Moreover, it is thought that targeting isoform-specific PI3K inhibitors 
will help to reduce the side effects and toxicity of treatment. For instance, the 
ability to target p110α and p110β only, while sparing p110γ and p110δ might 
avoid side-effects associated with toxicity to immune cells. 
Several p110α isoform-specific inhibitors are currently being evaluated in 
phase I clinical trials, such as BYL719, MLN1117 and GDC-0032 (Brana and 
Siu). The clinical trial of BYL719 is the first PI3K inhibitor study with molecular 
prescreening from the dose escalation part, in which only patients with PIK3CA 
mutation or amplification were enrolled to the trial (NCT01219699). TGX-221 is 
a cell permeable analogue of LY294002. It is a specific inhibitor of p110β with an 
IC50 of 5 nM and a 1000-fold higher selectivity over p110α. The main therapeutic 
utility of this compound seems to be as an anti-thrombotic agent (Jackson et al., 
2005). IC87114 is a p110δ-specific inhibitor which inhibits proliferation of acute 
myeloid leukemia (AML) cells but not normal haematopoietic progenitor cells, 
suggesting an application for the treatment of this disease (Sujobert et al., 2005; 
Billottet et al., 2006). IC87114 was a preclinical precursor of CAL-101, which is 
currently the only delta isoform-specific inhibitor in clinical trials for oncology 
applications (Herman et al., 2010). CAL-101 is currently in phase II safety and 
efficacy study in relapsed or refractory Hodgkin lymphoma (NCT01393106). 
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1.5 Predictive biomarkers in cancer treatment 
Personalized cancer medicine is based on the concept of providing the right 
treatment to the right individual. Over the past few years, strong associations were 
observed between the presence of kinase mutations and response to molecular 
targeted drug response. For instance, chronic myeloid leukemia (CML) patients 
with Bcr-Abl aberration show a high response rate to the Bcr-Abl kinase inhibitor 
imatinib (Gadzicki et al., 2005). Other well-known examples include associations 
between EGFR mutations and response to EGFR inhibitors (gefitinib or erlotinib) 
in non-small cell lung cancer (NSCLC) (Paez et al., 2004) and HER2 
amplification and response to HER2 inhibitors (trastuzumab or lapatinib) in breast 
cancer (Smith et al., 2007). These findings strongly support the notion that 
predictive biomarkers are useful for the selection of patients who are most likely 
to respond to a given targeted therapy.   
 Studies with agents such as gefitinib have revealed that differences in the 
frequency of predictive markers between different ethnic groups can help to 
identify the most responsive patient subgroups (Paez et al., 2004). Emerging 
approaches using mutually exclusive markers, such as KRAS and BRAF mutations 
to predict resistance to cetuximab (Di Nicolantonio et al., 2008) have also 
demonstrated how an understanding of co-occurrence patterns of pathway 




1.6 Predictive biomarkers for response to PI3K inhibitors 
 Among the drug determinants that have been identified for PI3K inhibitors, 
PIK3CA mutations were found to be a drug determinant consistently in a number 
of studies (Serra et al., 2008; Brachmann et al., 2009; Ihle et al., 2009; O'Brien et 
al., 2010; Sanchez et al., 2011; Santiskulvong et al., 2011). Indeed, the 
association between PIK3CA mutation and drug response has been validated in a 
larger panel of cancer cell lines comprising of breast, ovarian and endometrial 
cancer cells using CH5132799 (Tanaka et al., 2011). The effect of PIK3CA 
mutation in conferring drug sensitivity has also been confirmed in a mouse model, 
in which treatment of BEZ235 to the p110α H1047R driven lung 
adenocarcinomas led to remarkable tumour regression (Engelman et al., 2008).  
HER2 amplification has also repeatedly been shown to be associated with 
sensitivity of PI3K inhibitors in breast cancer (Brachmann et al., 2009; O'Brien et 
al., 2010). It has been demonstrated that cells harbouring amplification of HER2 
are dependent on PI3K pathway activation and sensitive to its inhibition through 
targeting of PI3K (Brachmann et al., 2009; O'Brien et al., 2010; Tanaka et al., 
2011). 
PTEN deficiency has been reported to predict PI3K pathway inhibitor 
response in ovarian cancer (Ihle et al., 2009; Santiskulvong et al., 2011). 
However, the association between PTEN loss and response is less clear in breast 
cancer (She et al., 2008; Brachmann et al., 2009; Lehmann et al., 2011; Tanaka et 
al., 2011; Weigelt and Downward). In one study, breast cancer cell lines with 
PTEN loss were found to be sensitive to BKM120 (Sanchez et al., 2011). In 
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contrast, Brachmann et al. study showed PTEN null breast cancer cells to be 
preferentially resistant to treatment with BEZ235 (Brachmann et al., 2009). This 
suggests that the correlation between PI3K aberrations and drug sensitivity could 
be tumour subtype specific.  
Nonetheless, in the evaluation of the in vitro efficacy of 25 PI3K pathway 
inhibitors in a panel of 39 human cancer cell lines, PIK3CA, HER2, PTEN 
mutations were not associated with sensitivity to PI3K inhibitors (Dan et al., 
2010). Instead, cell lines with high p-AKT were found to be more responsive to 
PI3K pathway inhibitors than those with lower expression levels. Recently, a 
large scale systemic identification of genetic drug determinants was performed 
using 639 human cancer cell lines, including 17 GC and 34 CRC cell lines and 
tested with 130 drugs (Garnett et al., 2012). These cancer cell lines were 
subjected to sequencing of full coding exons of 64 commonly mutated cancer 
genes, copy number variation profiling and gene expression profiling.  Among the 
130 drugs, 3 of them were PI3K inhibitors, AZD6428 (p110β specific inhibitor), 
BEZ235 (PI3K/mTOR inhibitor) and GDC-0941 (PI3K inhibitor). In this study, 
significant association was identified between PIK3CA mutations and the 
sensitivity of AZD6428, but not with BEZ235 and GDC-0941. Furthermore, 
mutations of APC and KRAS were also reported to be associated with higher IC50 
value of PI3K inhibitors in this study.  The lack of consistent associations 
between PIK3CA mutation, HER2 amplification, PTEN deficiency and sensitivity 




1.7  Predictive biomarkers of PI3K inhibitors (clinical trials) 
To date, the association between PI3K pathway aberrations and the clinical 
outcome of phase I clinical trials is still inconclusive due to small sample size or 
lack of assessment of PI3K aberrations in the tumours (Bendell et al.; Hong et 
al.).  
A pooled analysis of patients treated with PI3K pathway inhibitors (mTOR 
or PI3K inhibitors) was performed by Janku et al. (Janku et al., 2012). In this 
study, advanced breast, cervical, endometrial and ovarian cancers were sequenced 
for the presence of activating PIK3CA mutations. A partial response was observed 
in 30% of the 23 patients with tumours harbouring a PIK3CA mutation in contrast 
to 10% of 70 patients whose tumours were PIK3CA wildtype (Janku et al.). 
However, the majority of the patients received combination therapies with an 
mTOR inhibitor and not a PI3K inhibitor.  
Some studies have begun to recruit patients with specific PI3K aberrations 
during the dose escalation part (Brana and Siu), except BYL719 (NCT01219699) 
and GSK2636771 (NCT01458067). The preliminary clinical results of BYL719 
has been recently presented (Juric D, 2012). A total of 35 patients have been 
enrolled and three patients whom received doses ≥ 270 mg/day demonstrated 
partial response. These responders were a breast cancer patient with estrogen 
positive receptor, a cervical cancer patient and a colorectal cancer patient with 
KRAS mutation. The clinical response observed in the colorectal cancer patient 
with co-existing KRAS and PIK3CA mutations contrasts with the preclinical 
finding that co-occurrence of these mutations conferred resistance to BYL719 
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(Brana and Siu). GSK2636771 (p110β isoform specific inhibitor) is currently 
being tested in a clinical trial of PTEN deficient malignancies due to the recent 
finding in preclinical models suggested that PTEN deficient cancers may depend 
on p110β rather than p110α signaling (Jia et al., 2008; Wee et al., 2008; Ni et 
al.). However, results from this trial have not yet been reported. 
 
1.8 Rationale for this study 
Major elements of the PI3K pathway are known to be mutated or amplified in GC 
and CRC. For instance, PIK3CA mutations have been reported in GC and CRC at 
a frequency of approximately 11% and 14%, respectively (Velho et al., 2005). In 
addition to mutation, GC also shows a high prevalence (~40%) of PIK3CA 
amplification (Byun et al., 2003). A high frequency of PTEN loss of expression 
has also been reported in GC (Bai et al., 2007) and CRC (18%) (Frattini et al., 
2007). The relatively high frequencies of these PI3K pathway aberrations suggest 
they may have clinical potential for the selection of GC and CRC patients to 
receive targeted PI3K pathway therapy. 
Over the past decade, studies on molecular-targeted drugs have conveyed 
important lessons for the further development of this class of agent (Martini et al., 
2011). Knowledge of PI3K pathway aberrations in GC and CRC tumours is still 
quite limited, especially (1), the co-occurrence patterns of individual aberrations 
and (2), geographic or ethnic differences in the frequency of aberrations. Such 
knowledge is critical if biomarkers are to be introduced routinely to stratify 
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patient populations based on their molecular characteristics for treatment with 
PI3K inhibitors. 
In addition, trials with imatinib and trastuzumab have shown that pre-
selection of patients for treatment based on biologically relevant predictive 
markers can improve drug efficacy (Esteva et al., 2002; Gianni et al., 2011). One 
of the limitations of extrapolating data from the literature in this field to GC and 
CRC is that the majority of preclinical studies have been performed in breast 
cancer cell lines. Moreover, the large scale studies provide poor information at the 
tumour type level. Predictive biomarkers could well be different between different 
tumour types. For instance, PTEN deletion was associated with drug sensitivity in 
ovarian cancer (Santiskulvong et al., 2011) but not in breast cancer (Brachmann et 
al., 2009). Therefore, it is necessary to identify predictive biomarkers for PI3K 
inhibitors specifically according to the cancer type.   
  
1.9 Aims of the study 
The aims of this study were: 
Aim 1: To consolidate knowledge on inter-ethnic frequencies, clinical 
associations and co-occurrence patterns of prominent PI3K pathway aberrations 
in GC and CRC using meta-analysis and single laboratory approaches.  
These results are addressed in Chapter 3. 
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Aim 2:  To screen and functionality evaluate predictive biomarkers that could 
determine sensitivity to PI3K inhibitors in GC and CRC cells 
(A) using OncoCarta in GC and CRC cells 
These results are addressed in Chapter 4.  
(B) using RNA-sequencing in PIK3CA wildtype GC cells. 









2 Materials and Methods 
2.1 Clinical samples 
Formalin-fixed and paraffin embedded (FFPE) tissue blocks of tumour samples 
selected for maximal tumour cell content, together with corresponding normal 
tissues were obtained from the Department of Pathology, National University 
Hospital. In all, 140 GC and 150 CRC cases from patients who underwent surgery 
for their disease during 1997-2008 were investigated. The clinicopathological 
features for each of these cases are listed in Table 3.4 and Table 3.5. This study 
was approved by the National University of Singapore Institutional Review Board 
(NUS 654). 
 
2.2 Cell lines 
A total of 36 GC and 15 CRC cell lines (Table 2.1) were obtained from American 
Type Culture Collection (ATCC), Japanese Collection of Research Bioresources 
(JCRB), Cell lines Service GmbH (CLS) and Yonsei Cancer Centre (Yonsei CC) 
and grown in RMPI 1640 or DMEM supplemented with a final concentration of 








Table 2.1. GC and CRC cell lines. 
Cell Line Tissue Type Source Catalog Number 
AGS Gastric ATCC CRL-1739 
Az521 Gastric JCRB JCRB0061 
CLS145 Gastric CLS NA 
Fu97 Gastric JCRB JCRB1074 
HGC27 Gastric CLS NA 
Hs738 Gastric ATCC CRL-7869 
Hs746T Gastric ATCC HTB-135 
IM95 Gastric JCRB JCRB1075.0 
KATOIII Gastric ATCC HTB-103 
MKN1 Gastric JCRB JCRB0252 
MKN28 Gastric JCRB JCRB0253 
MKN45 Gastric JCRB JCRB0254 
MKN7 Gastric JCRB JCRB1025 
MKN74 Gastric JCRB JCRB0255 
NCI-N87 Gastric ATCC CRL-5822 
NUGC2 Gastric JCRB JCRB0821 
NUGC3 Gastric JCRB JCRB0822 
NUGC4 Gastric JCRB JCRB0834 
OCUM1 Gastric JCRB JCRB0192 
RERF-GC-1B Gastric JCRB JCRB1009 
SCH Gastric JCRB JCRB0251 
SNU1 Gastric ATCC CRL-5971 
SNU16 Gastric ATCC CRL-5974 
SNU5 Gastric ATCC CRL-5973 
TMK1 Gastric Japan NA 
YCC1 Gastric Yonsei CC NA 
YCC3 Gastric Yonsei CC NA 
YCC6 Gastric Yonsei CC NA 
YCC7 Gastric Yonsei CC NA 
YCC10 Gastric  Yonsei CC NA 
YCC11 Gastric  Yonsei CC NA 
YCC16 Gastric  Yonsei CC NA 
YCC17 Gastric  Yonsei CC NA 
YCC18 Gastric  Yonsei CC NA 
YCC19 Gastric  Yonsei CC NA 
YCC20 Gastric  Yonsei CC NA 
CCK81 Colorectal JCRB JCRB0208 
COLO205 Colorectal ATCC CCL-222 
COLO320 Colorectal ATCC CCL-220.1 
DLD1 Colorectal ATCC CCL-221 
HCC56 Colorectal JCRB JCRB1037 
HCT116 Colorectal ATCC CCL-247 
HT29 Colorectal ATCC HTB-38 
LoVo Colorectal ATCC CCL-229 
LS513 Colorectal ATCC CRL-2134 
RCM1 Colorectal JCRB JCRB0256 
RKO Colorectal ATCC CRL-2577 
SW403 Colorectal ATCC CCL-230 
SW480 Colorectal ATCC CCL-228 
SW620 Colorectal ATCC CCL-227 






PI3K inhibitors (BSP-A and BSP-B (BAY1082439)) and a MEK inhibitor (BSP-
C) were obtained from Bayer HealthCare Pharmaceuticals (Bayer AG, 
Leverkusen, Germany). Commercially available PI3K inhibitors (NVP-BKM120, 
GDC-0941, XL-147 and BYL719) were purchased from Selleck Chemicals 
(Houston, TX). 
 
2.4 DNA extraction 
For FFPE, a single 15 µm section was cut from each block and processed 
according to methods described previously (Soong and Iacopetta, 1997). Cell line 
DNA extraction was performed using DNeasy kit (Qiagen) following the 
manufacturer’s protocol. 
 
2.5 RNA extraction 
Total RNA was isolated using RNeasy Mini kit (Qiagen) following the 
manufacturer’s protocol. Extracted RNA was treated with DNase I to remove 
possible genomic DNA contamination (Qiagen). The quality of RNA was 
assessed using Bioanalyzer (Agilent Technologies, Santa Clara, CA) with the 
RNA 6000 Nano kit.  Only RNA with RNA integrity number value greater than 8 
and with a 28S rRNA band at 4.9 kb that is twice that of the 18S rRNA band at 




2.6 Sanger sequencing 
Primers were designed to amplify PIK3CA exon 9 (forward: 5’ GAA TCC AGA 
GGG GAA AAA TA 3’; reverse: 5’ TTT AGC ACT TAC CTG TGA CTC CA 
3’) and exon 20 (forward: 5’ TTC GAA AGA CCC TAG CCT TAG A 3’; 
reverse: 5’ TGC TGT TTA ATT GTG TGG AAG ATC 3’), in which 196 bp and 
129 bp amplicons were generated for the respective primers. The majority (>80%) 
of mutations in PIK3CA have been observed in these two exons (Samuels et al., 
2004). A total of 50 ng DNA was amplified in a 25 µL reaction mix containing 1x 
FastStart Reaction Buffer, 2 mM magnesium chloride, 10 µM deoxynucleotide 
mix and 1 unit FastStart Taq Polymerase (Roche Diagnostics, Mannheim, 
Germany). PCR cycling comprised initial denaturation at 95
o
C for 4 min followed 
by 40 cycles of 30 sec at 95
o
C, 30 sec at 65
o
C (exon 9) or 60
o
C (exon 20), and 1 
min at 72
o
C before completion with 1 min at 72
o
C. PCR products were purified 
using ExoSAP-IT reagent (Affymetrix, Santa Clara, CA) before undergoing bi-
directional sequencing using the BigDye Terminator v3.0 kit (Life Technologies) 
with forward and reverse PCR primers respectively. Sequencing products were 
electrophoresed and analyzed on the ABI PRISM 3100 Genetic Analyzer using 





KRAS was amplified using primers (forward: 5’ AGG CCT GCT GAA AAT 
GAC TGA A 3’; reverse: 5’ biotin-TTA GCT GTA TCG TCA AGG CAC TCT 
3’). The PCR condition was 45 cycles of 95ºC for 30 sec, 60ºC for 30 sec and 
72ºC for 1 min, followed by 72ºC for 5 min. Amplified PCR product with 82 bp 
size were subsequently analysed by Pyrosequencing using the PSQ96MA 
instrument (Qiagen, Hilden, Germany). The reaction mix comprised of Pyro Gold 
Reagent kit (Qiagen), 1x annealing buffer (Qiagen), binding buffer at pH7.6 (10 
mM Tris-HCl, 2 M NaCl, 1mM EDTA, 1 mL/L Tween 20), 3 µL of streptavidin 
sepharose beads and 15 µM pyrosequencing primer (5’ CTT GTG GTA GTT 
GGA GCT 3’). The nucleotide dispensation order was TAC GAC TCA GAT 
GCG TAG (Dufort et al., 2009). 
 
2.8 Mutation analysis by Mass Spectrometry 
Mutation analysis of 304 nucleotide commonly mutated in cancer was performed 
by analyzing the OncoCarta panel (Table 2.2) using the Sequenom MassARRAY 
(Sequenom, San Diego, CA). Multiplexed PCR was performed in 5 μL volumes 
containing 0.8 μL of HPLC H2O, 1 unit of SQNM PCR enzyme, 20 ng of 
genomic DNA, 2 mM of MgCl2, 500 μM of dNTP and 2 μL of OncoCarta PCR 
primers. Thermocycling was performed at 94
o
C for 2 min followed by 45 cycles 
of 94
o
C for 30s, 56
o
C for 30s and 72
oC for 1 min. A total of 2 μL of shrimp 
alkaline phosphatase (SAP) mixture was added to the PCR product to deactivate 
unincorporated deoxynucleotides and the mixture was incubated at 37
o
C for 40 
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min followed by 85
o
C for 5 min. Primer extension was carried out using 5.4 pmol 
of each primer extension probe, 50 µmoL of the appropriate dNTP/ddNTP 
combination and 1.3 units of Thermosequenase. The mixture was incubated at 
94
o
C for 30 sec, followed by 40 cycles of 94
o
C for 5 sec, 52
o
C for 5 sec and 80
o
C 
for 5 sec. After the addition of a cation exchange resin to remove residual salt 
from the reactions, 7 µL of the purified primer extension reaction was loaded onto 
a matrix pad (3-hydoxypicoloinic acid) of a SpectroCHIP (Sequenom). 
SpectroCHIPs were analysed using a Bruker Biflex III matrix-assisted laser 



















Table 2.2. List of 29 genes screened for hotspot mutations OncoCarta panel. 
 
 
Ge n e Mu ta tio n No  o f a s s a y
ABL1
G250E, Q252H, Y253H, Y253F, E255K, E255V, D276G, F311L, T315I, F317L, M351T, E355G, F359V,
H396R
14
AKT1 V461L, P 388T, L357P , E319G, V167A, Q43X, E17de l, E17K 8
AKT2 S 302G, R371H 2
BRAF
R443T, R444W, R444Q, R462I, I463S , E586K, V600D, G615E, G464R, G464V/G464E, G466R, F468C,
G469S /G469E/G469A, G469V/G469R, D594V/D594G, F595L, G596R, L597S /L597R, L597Q/L597V,
T599I, V600E/V600K, V600R/V600L, K601N, K601E
24
CDK R24C, R24H 2
CTNNB1
D32N/D32H/D32Y, S 33P , S 33Y/S 33C/S 33F, G34R, G34E/G34V, S 37A, S 37Y/S 37C/S 37F, T41A/T41S ,
T41I, S 45P , S 45Y/S 45C/S 45F
11
EGFR
R108K, T263P , A289V, G598V, E709K/E709H, E709A/E709G/E709V, G719S /G719C, G719A,
M766_A767insAI, S 768IV769_D770insAS V, V769_D770insCV, D770_N771>AGG, D770_N771insG,
N771_P 772>S VDNR, P 772_H773insV, H773>NP YH773_V774insNP H, H773_V774insP H,
H773_V774insH, V774_C775insHV, T790M, L858R, L861Q, L747_T750de l, P
insE746_A750de l,T751AT751AE746_T751de l,I 
insS 752_I759de lL747_E749de l,A750P E746_A750de lL747_E749de lL747_S 752de l, 
P 753S E746_T751de l,V insL747_S 752de l,Q insL747_S 752de l, E746_T751de l, S 752DL747_T750de l,
E746_T751de lL747_T751de l, E746_A750de l, V ins , A750P , S 752I/FT751, T751I, T751P , L747_Q ins ,
L755P , G776V, CA775_G776 insYVMA, P 780_Y781 insGS P
47
ERBB2 L755P , G776S /G776LC, G776V, CA775_G776 insYVMA, P 780_Y781 insGS P , S 779_P 780 insVGS 6
FBX4 S 8R, S 12L, L23Q, G30N, P 76T 5
FBXW7 R465C, R465H, R479G, R479Q/R479L 4
FGFR1 S 125L, P 252T 2
FGFR2 S 252W, Y376C 5
FGFR3 G370C, Y373C, A391E, K650Q/K650E, K650T/K650M, A281V 1
FLT3 I836de l, D835H/D835Y 2
GNAQ Q209P /Q209L 1
HRAS G12V/G12D, G13C/G13R/G13S , Q61H/Q61H, Q61L/Q61R/Q61P , Q61K 5
JAK2 V617F 1
KIT
D52N, Y503_F504insAY, W557R/W557R/W557G, V559D/V559A/V559G, V559I, V560D/V560G,
K550_K558de l, K558_V560de l, K558_E562de l, V559de l, V559_V560de l, V560de l, P 551_V555de l,
Y553_Q556de l, Y570_L576de l, E561K, L576P , P 585P , D579de l, K642E, D816V, D816H/D816Y, V825A,
E839K, M552L, Y568D, F584S
65
KRAS
G12A/G12C/G12D, G12F/G12R, G12S /G12V, G13V/G13D, A59T, Q61E/Q61K, G13A/G13V/G13D, T58I,
A59V, G60D
10
MAP2K1 F53S , K57N, D67N, Y134C, E203K/E203Q 5
MAP2K2 F57I, F57C, F57L, K61E, R388Q 5
MET R970C, T992I, Y1230C, Y1235D, M1250T 5
NRAS G12V/G12A/G12D, G12C/G12R/G12S , G13V/G13A/G13D, A18T, Q61H, G48S 6
PDGFRA
V561D, T674I, F808L, D846Y, N870S , D1071N, D842_H845de l, I843_D846de l, S 566_E571>K,
I843_S 847>T, D842V, N659K, D842Y,  D842F, Y849C
15
PIK3CA
R88Q, N345K, C420R, P 539R, E542K, E545K, Q546K, H701P , H1047R/H1047L, H1047Y, R38H, C901F,
M1043I/M1043I, E418K, E542Q, E542V, E545Q, E545A/E545G, Q546E, Q546P /Q546R, Q546H, M1004I,




RET C634R, C634W, C634Y, E632_L633de l, M918T, A664D 6
S OS 1 R248H, R688Q, H888Q 3
TP53





2.9 Copy number analysis 
DNA copy numbers were quantified by real-time PCR (qPCR) in 20 µL reaction 
mixes that consisted of 10 µL of 2x Taqman Genotyping Master Mix, 1 µL of 20x 
Taqman Copy Number Assay, 1 µL of 20x Taqman Copy Number reference 
assay (Life Technologies) and 20 ng of DNA. The pre-designed TaqMan Copy 
Number Assays used were PIK3CA_Hs02708380_cn (amplicon size: 110 bps), 
PTEN_Hs02724235_cn (amplicon size: 95 bps) and Ribonuclease P. Thermal 
cycling consisted of 10 min at 95°C followed by 40 cycles of 15 sec at 95°C and 
1min at 60°C in the ABI 7900 HT Sequence Detection System (Life 
Technologies). Each sample was analyzed in triplicate and the mean copy number 
was calculated using Copy Caller software (Life Technologies). Thresholds for 
defining gene amplification and loss were determined by analysis of normal tissue 
from 21 randomly selected cases of GC and CRC. Tumour samples were 
considered to show amplification (or loss) when their copy number was greater 
(or less) than two standard deviations of the median copy number observed in 
normal tissue. The median ± standard deviations of copy numbers in normal 
tissue for PIK3CA were 1.09±0.44 for GC and 1.25±0.48 for CRC, and for PTEN 





 Magnetic Kit (Epicentre Biotechnologies, Madison, WI) was used to 
remove the ribosomal RNA from the total RNA of the cell lines. A total of 5 µg 
RNA sample was combined with 4 µL of Ribo-Zero reaction buffer, 10 µL of 
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Ribo-Zero rRNA removal solution, and topped up with RNase-free water to 40 
µL.  The mixture was incubated at 68°C for 10 min, followed by incubation at 
room temperature for 5 min. The mixture was transferred to 1.5 mL eppendorf 
tube containing 225 µL of magnetic beads and was immediately mixed by 
pipetting at least 10 times. The tube was vortexed at medium setting for 10 sec 
and place at room temperature. After 5 min incubation, the mixture was vortexed 
and transferred to a 50°C heating block for 5 min, followed by transferring to a 
magnetic stand and leaving it to stand for at least 1 min until the solution 
appeared clear. The clear supernatant was removed and transferred to a new 1.5 
mL eppendorf tube. The rRNA-depleted RNA was further purified by Qiagen 
RNeasy TM MinElute Cleanup Kit (Qiagen). The amount of rRNA-depleted 
RNA was quantified by NanoDrop ® UV-Vis Spectrophotometer (Thermo 
Scientific, Wilmington, DE).  
RNA libraries were constructed according to the protocol of ScriptSeq
TM
 v2 
mRNA-Seq Library Preparation Kit (Epicentre Biotechnologies). RNA 
fragmentation was achieved by incubating 12 µL solution containing 50 ng of 
rRNA-depleted RNA, 1 µL RNA fragmentation solution, 2 µL cDNA synthesis at 
85°C for 5 min. The fragmentation reaction was stopped by placing the tube on 
ice. cDNA synthesis was achieved by adding 4 µL of the cDNA synthesis master 
mix containing 3 µL cDNA synthesis premix, 0.5 µL 100mM DTT and 0.5 µL 
StarScript reverse transcriptase to the fragmented RNA mixture. The reactions 
were incubated at 25°C for 5 min, 42°C for 20 min and were cooled to 37°C. 
Tubes were taken out from the PCR machine and 1 µL of finishing solution was 
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added, followed by 10 min incubation at 37°C and 3 min incubation at 95°C. The 
reactions were cooled to 25°C and terminal tagging master mix containing 7.5 µL 
terminal tagging premix and 0.5 µL DNA polymerase was added to each reaction. 
After this, the mixture was incubated at 25°C for 15 min, 95°C for 3 min and kept 
at 4°C. The generated cDNA was purified by Agencourt AMPure XP system 
(BeckmanCoulter, Brea, CA) according to the manufacturer’s protocol.  
Purified cDNA was amplified in a 50 µL reaction containing 25 µL of 
FailSafe PCR Premix E, 1 µL of forward PCR primer, 1 µL of barcode reverse 
PCR primer and 0.5 µL (1.25 U) of FailSafe PCR enzyme. PCR cycling 
comprising 1 min at 95°C, followed by 10 cycles of 30 sec at 95°C, 30 sec at 55 
°C and 3 min at 68 °C. After the last PCR cycle, the mixture was incubated at 68 
°C for 7 min in a Master Cycler. Post-PCR purification was performed by using 
the Agencourt AMPure XP system (BeckmanCoulter), as according to the 
manufacturer’s protocol. The quality of cDNA library was confirmed by 
Bioanalyzer (Agilent Technologies) using High sensitivity DNA chips. 
Paired-end sequencing and read length of 76 nucleotides were performed on 
an Illumina HiSeq
TM
2000 sequencing machine (San Diego, CA). Two barcoded 
samples were pooled together in a single lane of a flow cell (Illumina). 
Sequencing on the Illumina Hiseq
TM
2000 was performed with TruSeq PE Cluster 
Kit v3-cBot-Hs and Truseq SBS Reagent v3 sequencing kits (Illumina) according 
to manufacturer’s instructions.   
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The images generated by the sequencers were converted into nucleotide 
sequences by a base-calling pipeline. The raw reads were saved in the fastq 
format, and I removed reads with sequence adaptors and reads with more than 2% 
“N” bases. All subsequent analysis was based on clean reads. The reference 
sequences used were genome and transcriptome sequences downloaded from the 
UCSC website (version hg19). Clean reads were respectively aligned to the 
reference genome and transcriptome using BWA (Li and Durbin, 2010). No more 
than 3 mismatches were allowed in the alignment for each read.  The gene 
expression level was measured by the number of uniquely mapped reads per 
kilobase of exon region per million mapped reads (RPKM). The Log2 transformed 
RPKM values were used to identify the differentially expressed genes between 
sensitive and resistant cell lines based on the following criteria: -4>fold 
change>4.  
 
2.11 Quantitative reverse transcription -PCR (qRT-PCR) 
RNA from cell lines was collected using RNeasy Mini kit (Qiagen) and converted 
to cDNA using High Capacity cDNA Reverse Transcription Kit (Life 
Technologies). A 20 µL reverse transcription reaction contained 2 µL of 10x RT 
buffer, 0.8 µL of 25x dNTP Mix, 2 µL of 10x RT Random Primers, 1 µL 
MultiScribe Reverse Transcriptase and 2 μg of total RNA. Thermal cycling of 
reverse transcription consisted of 10 min at 25°C, 120 min at 37°C and 5 min at 
85°C. Primers were designed to amplify ACTB (forward: 5’ GTC GTC GAC 
AAC GGC TCC GG 3’; reverse: 5’ CCA CCA TCA CGC CCT GGT GC 3’) and 
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IGFBP3 (forward: 5’ TTC GAA AGA CCC TAG CCT TAG A 3’; reverse: 5’ 
TGC TGT TTA ATT GTG TGG AAG ATC 3’). qRT-PCR comprising 12.5 µL 
of Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific), 0.3 µM of 
forward primer, 0.3 µM of reverse primer and 100 ng of cDNA. Thermal cycling 
consisted of 10 min at 95°C followed by 40 cycles of 15 sec at 95°C and 1min at 
60°C in the ABI 7900 HT Sequence Detection System (Life Technologies). 
 
2.12 Immunohistochemistry  
Three 4 µm sections were obtained from tissue microarray blocks of GC and CRC 
described previously (Das et al., 2008) and which contained the same cases from 
which DNA was extracted. The sections were stained by immunohistochemistry 
using the BOND-MAX autostainer (Leica Microsystems, Buffalo Grove, IL) 
according to the manufacturer’s recommended protocols and reagents. The 
following proteins (antibody concentration, clone, source) were selected for 
analysis based on their published validation for functional sensitivity and 
specificity: p110α (1:300; 611398; BD Transduction Laboratories, San Jose, CA) 
(Lee et al.), PTEN (1:400; 6H2.1, Cascade Bioscience, Winchester, MA) (Goel et 
al., 2004; Nassif et al., 2004) and pAKT (Ser473) (1:200; 587F11, Cell-Signaling 
Technology, Beverly, MA) (Loupakis et al., 2009). The intensity of staining in 
tumour cytoplasm was scored independently on a scale of 0 to 3 by two 
pathologists who were blinded to the results for other aberrations. In cases of 
discordance, a consensus score was reached after discussion. For PI3K p110α and 
pAKT, tumours with an intensity score of 3 were considered to have high 
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expression, as reported previously (Oki et al., 2005). For PTEN, tumours without 
any staining (score 0) were considered to show PTEN loss, as described 
previously (Zhu et al., 2012). Endothelial cells in the neovascular capillaries and 
vessels were used as internal positive controls for PTEN. 
 
2.13 Drug proliferation assays 
Cells (3000 cells/well) were seeded in 96 well plates containing 90 µL media with 
10% FBS. After 24 h, 10 µL of drug diluted in DMSO was added to the plated 
cells with a final concentration ranging from 1-5000 nM. Cell viability was 
assessed after 72 h using CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI). The drug concentration that inhibited cell 
proliferation by 50% compared with vehicle controls (DMSO) was calculated and 
indicated as IC50 (Bhattacharya et al., 2012). 
 
2.14 Short interfering RNA experiments and cell viability assays 
ON-TARGETplus si-KRAS and si-IGFBP3 containing pools of 4 siRNAs per 
genes were purchased from Thermo Scientific. A total of 80 µL of cells (5000 
cells) and 1.6 mL of cells (3x10
5 
cells) were seeded in 96 and 6 well plate 
respectively, and transfected with siRNA using Lipofectamine 2000 (Life 
Technologies) at a final concentration of 25 nM. Assays were performed together 
with ON-TARGETplus non-targeting siRNA (Thermo Scientific) as a negative 
control. After 24 h incubation, media was removed from the wells and replaced 
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with new media. Cell viability was assessed by CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega).  
 To determine the combined effects of siRNA knockdown of target genes 
on sensitivity to PI3K inhibitors, different drug concentrations were added to the 
well after 24 h transfection as described above. Assays were performed in 
triplicate and the fractions of cell viability were normalized with control (non-
targeting siRNA). Cell viability was measured at 72 h after drug treatment using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega).  
 
2.15 Establishment of YCC1 isogenic cell lines 
Control plasmid, pBOBI-GFP was kindly provided by Dr Dominic Voon. The 
coding region of human IGFBP3 was cloned into a pBOBI vector (a kind gift of 
Vinay Tergoankar, IMCB, A*STAR) using 5’ XbaI and 3’ Xho1 sites. The 
sequence of IGFBP3 was confirmed by Sanger sequencing (Life Technologies). 
Lentiviruses were produced in HEK293T cells using ViraPower packaging 
vectors (Invitrogen) and FuGENE HD (Promega). Supernatants containing viral 
particles were harvested at 48 hours after transfection. For transduction with 
lentiviruses, YCC1 cells were incubated with virus-containing supernatants in the 
presence of 8 µg/mL polybrene (Sigma-Aldrich) for 24 hours before 




2.16 SDS-PAGE and western blot analysis 
Assessment of protein expression in cell culture extracts were performed by 
western blotting. Cell protein lysates were separated through 10% SDS-PAGE 
and transferred to nitrocellulose membrane. The membrane was blocked in 5% 
milk and then immunoblotted with the anti-phospho-AKT (Ser473), total AKT, 
phospho-ERK1/ERK2 (Thr202/Tyr204)), total ERK1/ERK2, p110α, GAPDH 
antibodies from Cell Signaling Technology. Anti-KRAS was purchased from 
Santa Cruz Biotechnology (Dallas, Texas). Anti-IGFBP3 was purchased from 
Sigma-Aldrich (St.Louis, MO). Primary antibodies were diluted in 5% bovine 
serum albumin (BSA) (Sigma-Aldrich) and were used at dilutions recommended 
by the manufacturers. Secondary anti-rabbit and anti-mouse were purchased from 





prime Western blotting detection reagent (GE 
Healthcare Biosciences, Pittsburgh, PA) according to the manufacturer’s 
instructions.  
 
2.17 Statistical analysis 
For meta-analysis, studies were combined using a random effects model, with 
weighting by the inverse of variance. Homogeneity amongst studies was assessed 
using the Cochran Q statistic and the I
2 statistic. The Likelihood ratio or Fisher’s 
exact test was used to test for differences in the frequency of aberrations between 
Asians and Caucasians, as well as associations with clinicopathological features. 
Fisher’s exact test was used to test for differences in PI3K aberrations between 
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GC and CRC. Binary logistic regression was used to test the significance of the 
association between different PI3K activation events. For survival analysis, 
univariate Cox proportional hazards regression analysis was performed to 
estimate hazard ratios. Multivariate Cox regression analysis (Method: Enter) of 
factors significant in univariate analysis was performed to identify independent 
prognostic factors. Correlations between drug sensitivity and mutation status, 
gene expression and protein expression were estimated by Spearman’s rank 
correlation method, and differences between groups were calculated with 
Student’s t test. Analyses were performed using Comprehensive Meta Analysis 
version 2.2 (Biostat, Englewood, NJ) and SPSS statistical software package for 
Microsoft Windows version 19.0 (SPSS, Chicago, IL). All tests of significance 
were two-sided, and p values<0.05 were considered significant. Quantile 
normalization of IC50 values was performed using R software. Clustering of GC 
cell lines was performed with MeV 4.4.01 software, using unsupervised 
hierarchical clustering analysis on the basis of Pearson’s dissimilarity as distance 
measure. 
 
2.18 Pathway analysis 
Differential expressed genes were uploaded to the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) software to analyze the genes 
that were involved in biological pathways. Parameters in a “Functional 
Annotation Tool” were set to retrieve pathway information from Kyoto 
Encyclopedia of Genes and Genomes (KEGG). Analysis of the gene biological 
44 
 
functions and pathways were performed using GO ANOVA analysis in the Partek 








3 Results: Phosphatidylinositol-3-kinase Pathway 
Aberrations in Gastric and Colorectal Cancer: Meta-analysis, 
Co-occurrence and Ethnic Variation 
 
3.1.1 Literature review 
Relevant publications were identified through a PubMed search in January 
2013 using the terms “PI3K and gastric cancer”, “PTEN and gastric cancer”, 
“AKT and gastric cancer”, “PI3K and colorectal cancer”, “PTEN and 
colorectal cancer”, and “AKT and colorectal cancer”. A restriction to human 
studies was applied. Other publications were identified from references cited 
in the retrieved articles. Information on the first author, year of publication, 
country of origin of the study population, frequencies of aberrations and total 
cases was recorded (Table 3.1). The country of origin of the study population 
was used to determine ethnicity, with East Asian populations defined as those 
from China, Hong Kong, Japan, Korea, Singapore and Malaysia, and 
Caucasian populations as those from Europe, Australia and North American 
countries. Studies on populations outside these two regions were annotated 
(Table 3.1), but not considered in the meta-analysis according to ethnicity. 
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Table 3.1. Frequencies of PI3K pathway aberrations in GC and CRC from previous publications and the 
current study. (continued next page) 
First Author Year PMID Cancer Type Study Population Ethnicity Aberration Method Aberrant Cases Total Cases Frequency 
Current Study 2013  Gastric  Asian PIK3CA Mutation Sanger (exon 9, 20) 3 79 4% 
Li VS 2005 15784156 Gastric Hong Kong Asian PIK3CA Mutation Sanger (exon 9, 18, 20) 4 94 4% 
Lee J 2012 22723903 Gastric Korea Asian PIK3CA Mutation Sequenom (OncoMap v4) 12 237 5% 
Lee JW 2005 16397024 Gastric Korea Asian PIK3CA Mutation SSCP (exon 9, 20) 12 185 6% 
Shi J 2012 22292935 Gastric China Asian PIK3CA Mutation Sanger (exon 9, 20) 8 113 7% 
Velho S 2005 15994075 Gastric Portugal Caucasian PIK3CA Mutation Sanger (exon 9, 20) 5 47 11% 
Corso G 2011 20937558 Gastric Portugal Caucasian PIK3CA Mutation Sanger (exon 9, 20) 9 63 14% 
Wang K 2011 22037554 Gastric Hong Kong Asian PIK3CA Mutation Exome Sequencing 3 22 14% 
Barbi S 2010 20398348 Gastric Italy Caucasian PIK3CA Mutation Sanger (exon 9, 20) 42 264 16% 
Zang ZJ 2012 22484628 Gastric Singapore Asian PIK3CA Mutation Exome Sequencing 3 15 20% 
Samuels Y 2004 15016963 Gastric USA Caucasian PIK3CA Mutation Sanger (all exons) 3 12 25% 
Yasutaka  2012 23236232 Gastric Japan Asian PIK3CA Mutation Pyrosequencing (exon 1, 9, 20) 20 231 9% 
           
Kiyose S 2012 22691185 Gastric Japan Asian PIK3CA Amplification FISH 10 353 3% 
Byun DS 2003 12569555 Gastric Korea Asian PIK3CA Amplification PCR (semi-quantitative) 17 55 31% 
Current Study 2013  Gastric  Asian PIK3CA Amplification QPCR 36 79 46% 
Shi J 2012 22292935 Gastric China Asian PIK3CA Amplification QPCR 88 131 67% 
           
Current Study 2013  Gastric  Asian PTEN Deletion QPCR 1 79 1% 
Mina S 2012 22639407 Gastric Germany Caucasian PTEN Deletion FISH 8 180 4% 
Oki E 2005 16051030 Gastric Japan Asian PTEN Deletion Capillary Electrophoresis 13 76 17% 
Oki E 2006 16704528 Gastric Japan Asian PTEN Deletion Capillary Electrophoresis 13 76 17% 
Byun DS 2003 12569555 Gastric Korea Asian PTEN Deletion PCR (semi-quantitative) 14 55 25% 
Li YL 2005 15633233 Gastric China Asian PTEN Deletion Capillary Electrophoresis 9 30 30% 
           
Current Study 2013  Gastric Singapore Asian p110α High BD Biosciences Pharmingen, 1:300 4 79 5% 
           
Bai Z 2007 18184409 Gastric China Asian PTEN Loss Zymed 1:50 27 91 30% 
Yang L 2003 12508347 Gastric China Asian PTEN Loss Maixim Biotech 96 184 52% 
Current Study 2013  Gastric  Asian PTEN Loss Cascade Bioscience 6H2.1, 1:400 43 79 54% 
Yang Z 2013 22521126 Gastric China Asian PTEN Loss Abcam ab76431, 1:150 30 50 60% 
Bamias A 2010 20130877 Gastric Greece Caucasian PTEN Loss Dako 6H2.1, NA 51 66 77% 
Fei G 2002 11953696 Gastric Germany Caucasian PTEN Loss Chemicon 21 26 81% 
           
Current Study 2013  Gastric Singapore Asian pAKT High Cell Signaling, 587F11, 1:200 14 79 18% 
Oki E 2005 15900596 Gastric Japan Asian pAKT High Cell Signaling, 1:10 22 76 29% 
Yasutaka Sukawa 2012 23236232 Gastric Japan Asian pAKT High Cell Signaling, 1:100 119 231 52% 
Murakami D 2007 17334718 Gastric Japan Asian pAKT High Cell Signaling, 1:100 81 140 58% 
Cinti C 2008 18841391 Gastric Italy Caucasian pAKT High NEB 34 50 68% 
Nam SY 2003 14678019 Gastric Korea Asian pAKT High NEB 237 301 79% 
Murayama T 2009 19223902 Gastric Japan Asian pAKT High Cell Signaling, 1:50 94 109 86% 
           
Ching-Shian Leong V 2008 19027487 Colorectal Malaysia Asian PIK3CA Mutation Sanger (exon 9, 20) 0 24 0% 
Balschun K 2011 21704278 Colorectal Germany Caucasian PIK3CA Mutation Sanger (exon 20) 0 20 0% 
Patel H 2007 17721920 Colorectal UK Caucasian PIK3CA Mutation Sanger (exon 9, 20) 5 127 4% 
Soeda H 2012 22638623 Colorectal Japan Asian PIK3CA Mutation Sanger (exon 9, 20) 2 43 5% 
Ohta M 2008 18619647 Colorectal Japan Asian PIK3CA Mutation Sanger (exon 9, 20) 4 52 8% 
He Y 2009 19903786 Colorectal the Netherlands Caucasian PIK3CA Mutation Sanger (exon 9, 20) 19 240 8% 
Ollikainen M 2007 17471559 Colorectal Finland Caucasian PIK3CA Mutation SSCP(exon 1, 9, 20) 6 70 9% 
Tol J 2010 20413299 Colorectal the Netherlands Caucasian PIK3CA Mutation Sanger (exon 9, 20) 43 436 10% 
Current Study 2013  Colorectal Singapore Asian PIK3CA Mutation Sanger (exon 9, 20) 12 116 10% 
Kato S 2007 17590872 Colorectal Japan Asian PIK3CA Mutation Sanger (exon 9, 20) 18 158 11% 
Prenen H 2009 19366826 Colorectal Belgium Caucasian PIK3CA Mutation Sequenom (exon 9, 20) 23 200 12% 
Tian Sun 2012 22798500 Colorectal Netherlands Caucasian PIK3CA Mutation Sanger (exon 9, 20) 44 381 12% 
Lurkin I 2010 20098682 Colorectal Netherlands Caucasian PIK3CA Mutation Sanger (exon 9, 20) 34 294 12% 
Sartore-Bianchi A 2009a 19806185 Colorectal Italy Caucasian PIK3CA Mutation Sanger (exon 9, 20) 17 132 13% 
Perrone F 2009 18669866 Colorectal Italy Caucasian PIK3CA Mutation Sanger (exon 9, 20) 4 31 13% 
47 
 
Velho S 2005 15994075 Colorectal Portugal Caucasian PIK3CA Mutation SSCP (exon 9, 20) 14 103 14% 
Velho S 2008 18782444 Colorectal Portugal Caucasian PIK3CA Mutation Sanger (exon 9. 20) 14 103 14% 
Sartore-Bianchi A 2009b 19223544 Colorectal Italy Caucasian PIK3CA Mutation Sanger (exon 9, 20) 15 110 14% 
Ekstrand AI 2010 19731079 Colorectal Sweden Caucasian PIK3CA Mutation Sanger (exon 9, 20) 5 36 14% 
PERKins G 2010 20049837 Colorectal France Caucasian PIK3CA Mutation Sanger (NA) 6 42 14% 
Nosho K 2008 18516290 Colorectal USA Caucasian PIK3CA Mutation Pyrosequencing (exon 9, 20) 91 590 15% 
Souglakos J 2009 19603024 Colorectal Greece Caucasian PIK3CA Mutation Sequenom (exon 9, 20) 26 168 15% 
Benvenuti S 2008 18022911 Colorectal Italy Caucasian PIK3CA Mutation Sanger (exon 9, 20) 28 175 16% 
Barault L 2008 18224685 Colorectal France Caucasian PIK3CA Mutation Sanger (exon 1, 2, 9, 20) 98 586 17% 
Ogino S 2009 19704056 Colorectal USA Caucasian PIK3CA Mutation Pyrosequencing (exon 9, 20) 75 439 17% 
Simi L 2008 18628094 Colorectal Italy Caucasian PIK3CA Mutation HRMA (exon 9, 20) 20 116 17% 
Ogino S 2009 19237633 Colorectal USA Caucasian PIK3CA Mutation Pyrosequencing (exon 9, 20) 82 450 18% 
Campbell IG 2004 15520168 Colorectal Australia Caucasian PIK3CA Mutation SSCP, DHPLC (all exons) 6 32 19% 
Frattini M 2005 16322273 Colorectal Italy Caucasian PIK3CA Mutation Same as Samuels 12 60 20% 
Miyaki M 2007 17546593 Colorectal Japan Asian PIK3CA Mutation SSCP (exon 1, 7, 9, 20) 7 34 21% 
Samuels Y 2004 15016963 Colorectal USA Caucasian PIK3CA Mutation Sanger (all exons) 74 234 32% 
TCGA 2012 22810696 Colorectal USA Caucasian PIK3CA Mutation Exome Sequencing 34 276 12% 
           
Current Study 2013  Colorectal Singapore Asian PIK3CA Amplification QPCR 5 116 4% 
Ollikainen M 2007 17471559 Colorectal Finland Caucasian PIK3CA Amplification QPCR 5 67 7% 
Patel H 2007 17721920 Colorectal UK Caucasian PIK3CA Amplification QPCR 33 70 
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Current Study 2013  Colorectal Singapore Asian PTEN Deletion QPCR 9 116 8% 
Nassif NT 2004 14724591 Colorectal Australia Caucasian PTEN Deletion Capillary Electrophoresis 7 41 17% 
Goel A 2004 15126336 Colorectal USA Caucasian PTEN Deletion Capillary Electrophoresis 6 26 23% 
           
Current Study 2013  Colorectal Singapore Asian p110α High BD Biosciences Pharmingen, 1:300 1 116 1% 
Ekstrand AI 2010 19731079 Colorectal Sweden Caucasian p110α High Cell Signaling 4254, 1:50  24 49 49% 
           
Tamer Colakoglu 2008 18440486 Colorectal Turkey Caucasian PTEN Loss Neomarkers Ab4 4 76 5% 
Negri FV 2010 19953097 Colorectal Italy Caucasian PTEN Loss Millipore 5 43 12% 
Razis E 2008 18700047 Colorectal Greece Caucasian PTEN Loss Novocastra, 28H6 10 72 14% 
Frattini M 2005 16322273 Colorectal Italy Caucasian PTEN Loss Neomarkers , 1:50 7 40 18% 
Laurent-Puig P 2009 19884556 Colorectal France Caucasian PTEN Loss R&D Systems AF847 31 162 19% 
Molinari F 2009 19293803 Colorectal Switzerlandd Caucasian PTEN Loss Neomarkers, 1:50 8 38 21% 
Ekstrand AI 2010 19731079 Colorectal Sweden Caucasian PTEN Loss Cell Signaling 9559, 1:100 11 49 22% 
Nassif NT 2004 14724591 Colorectal Australia Caucasian PTEN Loss Cascase bioscience 6H2.1 10 41 24% 
Goel A 2004 15126336 Colorectal USA Caucasian PTEN Loss Cascase bioscience 6H2.1 3 10 30% 
Sartore-Bianchi A 2009a 19806185 Colorectal Italy Caucasian PTEN Loss Thermo Fisher Scientific, 1:200;  41 114 36% 
Ollikainen M 2007 17471559 Colorectal Finland Caucasian PTEN Loss Cascase bioscience 6H2.1 24 62 39% 
Sartore-Bianchi A 2009b 19223544 Colorectal Italy Caucasian PTEN Loss Thermo Fisher Scientific, 1:200;  32 81 40% 
Frattini M 2007 17940504 Colorectal Italy Caucasian PTEN Loss Neomarkers, 1:50 11 27 41% 
Tol J 2010 20413299 Colorectal the Netherlands Caucasian PTEN Loss Dako, 1:100 207 493 42% 
Loupakis F 2009 19398573 Colorectal Italy Caucasian PTEN Loss Neomarkers 17.A, 1:20  36 85 42% 
Mao C 2012 22586484 Colorectal China Asian PTEN Loss Unknown, 1:50 33 69 48% 
Jang KS 2010 20102402 Colorectal Korea Asian PTEN Loss Novocastra Laboratories, 1:200 241 482 50% 
Sawai H 2008 19036165 Colorectal Japan Asian PTEN Loss Santa Cruz, 28H6, 1:300 52 69 75% 
Current Study 2013  Colorectal Singapore Asian PTEN Loss Cascade Bioscience 6H2.1, 1:400 91 116 78% 
           
Schmitz KJ 2007 17149612 Colorectal Germany Caucasian pAKT High Cell Signaling, 1:20 28 133 21% 
Current Study 2013  Colorectal Singapore Asian pAKT High Cell Signaling, 587F11, 1:200 25 116 22% 
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3.1.2 Frequency of PI3K pathway aberrations according to meta-analysis 
Figure 3.1 and Table 3.2 summarize the frequencies of PI3K pathway aberrations 
obtained from the meta-analyses of all relevant publications and according to 
ethnicity. Details of the frequencies from individual studies and the methods used 
are provided in Table 3.1. The results from meta-analysis indicated that PTEN 
loss and high pAKT expression are the most frequent type of PI3K pathway 
aberration, with each found in approximately half of GC cases. PTEN loss was 
present in one-third of CRC cases and high p110α and pAKT expression was in 
half of CRC cases. The frequencies of PIK3CA mutations and amplifications were 
in the range of 12-23% for both GC and CRC, with PIK3CA amplification being 
about twice as common as mutation in both cancer types (Table 3.2).  
GC from East Asian patients showed significantly fewer PIK3CA 
mutations than Caucasian patients (7% vs. 15% respectively) but more frequent 
PTEN deletion (23% vs. 4%; Figure 3.1). The increased incidence of PTEN 
deletion in East Asian GC patients was not reflected in PTEN loss however, 
which was significantly lower compared to Caucasians (47% vs 78%). In contrast 
to GC, PTEN loss in CRC was more frequent in Caucasians compared to East 
Asians (58% vs 26%). It should be noted however that with the exception of 
PIK3CA mutation, a high level of study heterogeneity (I
2
>80) was observed for 







Figure 3.1. Frequencies of PI3K pathway aberrations in GC and CRC from published studies and laboratory analysis in the 
current study. The centre of each circle represents the frequencies reported in respective studies. The size of each circle is 
proportional to the sample size of the study. Studies on Caucasian populations are indicated by red circles, East Asian populations by 
blue circles, and the current study by black circles. 
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Table 3.2. Summarized frequencies of PI3K pathway aberrations from meta-analysis of published studies of GC and CRC, 
and laboratory analysis in the current study. 
 
  Meta-analysis (All Studies) Meta-analysis (Caucasian Studies) Meta-analysis (East Asian Studies)   
Aberration Frequency [95%CI] Studies (n)1 I2  (%) Frequency [95%CI] Studies (n)1 I2  (%) Frequency [95%CI] Studies (n)1 I2 (%) Current Study 





    
Gastric Cancer 
          
PIK3CA Mutation2 12.1% [9.8-14.9] 5 (672) 66.2 15.1% [11.8-19.1] 3 (374) NA 6.7% [4.4-10.2]* 2 (298) NA 3.8% (3/79) 
PIK3CA Amplification 23.2% [2.6-77.3] 3 (539) 98.5 NA NA NA 23.2% [2.6-77.3] 3 (539) 98.5 45.6% (36/79) 
PTEN Deletion 15.6% [11.4-20.9] 4 (341) 86.9 4.4% [2.2-8.6] 1 (180) NA 23.0% [16.4-31.2]* 3 (161) 19.3 1.3% (1/79) 
PI3K High NA NA NA NA NA NA NA NA NA 5.1% (4/79) 
PTEN Loss 68.9% [59.8-76.9] 5 (417) 90.1 78.2% [68.6-85.5] 2 (92) NA 46.7% [30.6-63.6]* 3 (325) 87.3 54.4% (43/79) 
pAKT High 66.1% [54.9-75.8] 6 (907) 95 68.0% [54.0-79.4] 1 (50) NA 62.8% [43.7-78.6] 5 (857) 96 17.7% (14/79) 
Colorectal Cancer 
          
PIK3CA Mutation2 12.4% [10.7-14.2] 19 (3756) 57.5 12.8% [10.7-14.2] 15 (3479) 61 9.1% [5.8-14.0] 4 (277) 8.7 10.3% (12/116) 
PIK3CA Amplification 21.7% [2.6-74.5] 2 (137) 95.3 21.7% [2.6-74.5] 2 (137) 95.3 NA NA NA 4.3% (5/116)Ϯ 
PTEN Deletion 19.6% [11.7-30.9] 2 (67) NA 19.6% [11.7-30.9]Ϯ 2 (67) NA NA NA NA 7.8% (9/116) 
PI3K High 49.0% [35.4-62.7] 1 (49) NA 49.0% [35.4-62.7] 1 (49) NA NA NA NA 0.9% (1/116) 
PTEN Loss 32.1% [25.5-39.6]Ϯ 16 (1905) 90.4 24.0% [17.7-31.7]Ϯ 13 (1285) 85.5 57.6% [42.2-71.7]* 3 (620) 86.7 
78.4% 
(91/116)Ϯ 
pAKT High 50.7% [43.2-58.1]Ϯ 7 (663) 91.2 49.8% [26.2-73.6]Ϯ 4 (393) 95.3 50.7% [42.9-58.6]Ϯ 3 (270) 34.8 21.6% (25/116) 
 
1
Number of studies (number of cases);  
2
 only studies which sequenced exon 9 and exon 20 of PIK3CA were included 
* p value <0.05, Asian vs Caucasian;  Ϯ indicates p value <0.05 between GC and CRC; NA= not available 
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3.1.3 Frequency of PI3K pathway aberrations according to single laboratory 
analysis 
The 6 aberrations were evaluated in a single cohort of 140 GC and 150 CRC cases 
from a Singaporean population. These were analyzed using Sanger sequencing to 
detect PIK3CA mutations in exons 9 and 20, qPCR quantification of DNA copy 
numbers for PIK3CA and PTEN, and IHC for the expression of PI3K (p110α), 
PTEN and pAKT. Representative examples of these analyses are shown in Figure 
3.2. Complete data for all 6 aberrations was obtained from 79 GC and 116 CRC 
cases and hence the subsequent analyses were restricted to these cases. 
Figure 3.1 shows the frequency of aberrations observed in the present 
study (black circles) compared to results from the meta-analysis of East Asian 
patients. For both GC and CRC, the frequency of PIK3CA mutations was not 
significantly different to results from other East Asian studies (GC: 4% vs 7%; 
CRC: 10% vs 9%). However, in keeping with the high level of study 
heterogeneity noted earlier in the meta-analysis, a poor concordance was observed 
for the remaining aberrations.  
The use of consistent analytical methods for PI3K pathway aberration 
allowed GC and CRC to be compared directly. Significant differences in the 
frequencies of PIK3CA amplification (46% vs. 4%, respectively) and PTEN loss 
(54% vs. 78%) were observed (Figure 3.1). 
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Figure 3.2. Representative data from Sanger sequencing, qPCR and IHC. (A) Representative chromatograms from Sanger 
sequencing of PIK3CA mutations of E542K (left panels) and H1047R (right panels) in normal tissue (upper panels) and tumour (lower 
panels). (B) Distribution of copy numbers for PIK3CA (left panel) and PTEN (right panel) in tumour (T) and normal tissue (N) from 
gastric cancer (GC) and colorectal cancer (CRC). The values of the mean ± 2 standard deviations are indicated for each group of 
values. (C) Representative images of immunohistochemistry for p110α (left panel) PTEN (middle panels) and p-AKT (right panels) 
expression in GC and CRC (40x magnification). 
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3.1.4 Co-occurrence of PI3K pathway aberrations 
Figure 3.3 displays the co-occurrence of PI3K pathway alterations in individual 
GC and CRC samples from the current laboratory analysis. At least one PI3K 
pathway aberration was found in 86% of GC and 90% of CRC samples. The 
majority of aberrations were mutually exclusive, with 52% of GC and 60% of 
CRC having just one aberration. The genetic aberrations in particular showed rare 
co-occurrence, with only 3/65 (5%) cases showing two aberrations (PIK3CA 
mutation and amplification in GC, PIK3CA amplification and PTEN deletion in 
GC, PIK3CA mutation and PTEN deletion in CRC). The analysis of co-
occurrence also revealed the two most common aberrations in GC were PTEN 
loss alone (27%) and PIK3CA amplification/PTEN loss (20%), while in CRC they 
















Figure 3.3. Co-occurence patterns for PI3K pathway aberrations in (A) GC 
and (B) CRC. Each column represents a tumour sample and each row 
corresponds to a PI3K aberration.Tumours are grouped according to the number 
of observed aberrations in each tumour (0, 1, 2 or 3). Green and red bars represent 







3.1.5 Association between PI3K pathway aberrations 
Pair-wise association analysis was performed between different PI3K pathway 
aberrations to assess the relationship of aberrations to each other (Table 3.3).The 
only significant association observed was between PTEN loss and high pAKT 
expression in GC (p=0.04). Other expected associations, such as between high 
pAKT expression and PIK3CA mutation, PIK3CA amplification, PTEN deletion 
or PTEN loss, did not reach significance. 
 
3.1.6 Associations with clinicopathological features 
The frequencies of PI3K pathway aberrations according to clinicopathological 
features in GC and CRC are shown in Table 3.4 and Table 3.5, respectively. The 
frequencies of the two most common patterns of aberration from analysis of co-
occurrence described above were also examined. In GC, PIK3CA amplification 
was more frequent in older patients (p=0.04). In CRC, PTEN loss alone was more 
common in female patients (p=0.02) and PTEN loss/high pAKT was more 







Table 3.3. Association between PI3K pathway aberrations in GC and CRC. Odds ratio (95% CI). 
 
  PIK3CA Amplification PTEN Deletion PI3K High PTEN Loss p-AKT High 
Gastric Cancer      
PIK3CA Mutation 0.59 (0.05-6.74) NA NA 0.41 (0.04-4.65) NA 
PIK3CA Amplification  NA NA 1.65 (0.67-4.04) 0.6 (0.18-2.02) 
PTEN Deletion   NA NA NA 
PI3K High    NA NA 
PTEN Loss     0.27* (0.08-0.94) 
      
Colorectal Cancer      
PIK3CA Mutation NA 1.10 (0.13-9.56) 1.53 (0.30-7.85) 0.33 (0.10-1.16) 0.70 (0.14-3.44) 
PIK3CA Amplification  NA NA 0.17 (0.03-1.05) NA 
PTEN Deletion   NA 2.31 (0.28-19.43) 3.28 (0.81-13.27) 
PI3K High    NA NA 
PTEN Loss     0.84 (0.29-2.38) 





























& PTEN Loss 
Ethnicity         
  Chinese (68) 3 (4%) 30 (44%) 1 (1%) 3 (4%) 37 (54%) 12 (18%) 19 (28%) 13 (19%) 
  Non-Chinese (11) 0 (0%) 6 (55%) 0 (0%) 1 (9%) 6 (55%) 2 (18%) 2 (18%) 3 (27%) 
Gender         
  Male (64) 3 (5%) 29 (45%) 1 (2%) 4 (6%) 33 (52%) 12 (19%) 15 (23%) 13 (20%) 
  Female (15) 0 (0%) 7 (47%) 0 (0%) 0 (0%) 10 (67%) 2 (13%) 6 (40%) 3 (20%) 
Age         
 <69 (37) 3 (8%) 12 (32%)* 1 (3%) 0 (0%) 21 (57%) 7 (19%) 12 (32%) 6 (16%) 
>69 (42) 0 (0%) 24 (57%)* 0 (0%) 4 (10%) 22 (52%) 7 (17%) 9 (21%) 10 (24%) 
Stage         
  I & II (30) 2 (7%) 10 (33%) 0 (0%) 1 (3%) 15 (50%) 7 (23%) 8 (27%) 6 (20%) 
  III & IV (49) 1 (2%) 26 (53%) 1 (2%) 3 (6%) 28 (57%) 7 (14%) 13 (27%) 10 (20%) 
Differentiation         
  Well/Moderate (23) 0 (0%) 8 (35%) 0 (0%) 1 (4%) 10 (43%) 6 (26%) 5 (22%) 5 (22%) 
  Poor/NOS (56) 3 (5%) 28 (50%) 1 (2%) 3 (5%) 33 (59%) 8 (14%) 16 (29%) 11 (20%) 
Tumour Size         
 <4cm (32) 1 (3%) 16 (50%) 0 (0%) 3 (9%) 14 (44%) 6 (19%) 5 (16%) 8 (25%) 
>4cm (47) 2 (4%) 20 (43%) 1 (2%) 1 (2%) 29 (62%) 8 (17%) 16 (34%) 8 (17%) 
Perforation          
  Absent (75) 3 (4%) 35 (47%) 1 (1%) 4 (5%) 41 (55%) 14 (19%) 19 (25%) 16 (21%) 
  Present (4) 0 (0%) 1 (25%) 0 (0%) 0 (0%) 2 (50%) 0 (0%) 2 (50%) 0 (0%) 
Lauren classification         
  Intestinal (48) 1 (2%) 23 (48%) 1 (2%) 4 (8%) 26 (54%) 9 (19%) 11 (23%) 12 (25%) 
  Non-intestinal (31) 2 (6%) 13 (42%) 0 (0%) 0 (0%) 17 (55%) 5 (16%) 10 (32%) 4 (13%) 
Lymphatic invasion         
  Absent (36) 2 (6%) 14 (39%) 0 (0%) 1 (3%) 19 (53%) 5 (14%) 7 (19%) 7 (19%) 
  Present (43) 1 (2%) 22 (51%) 1 (2%) 3 (7%) 24 (56%) 9 (21%) 10 (23%) 9 (21%) 
Perineural invasion         
  Absent (36) 2 (6%) 13 (36%) 0 (0%) 2 (6%) 18 (50%) 6 (17%) 6 (17%) 6 (17%) 
  Present (43) 1 (2%) 23 (53%) 1 (2%) 2 (5%) 25 (58%) 8 (19%) 11 (26%) 9 (21%) 
H.pylori         
  Absent (69) 3 (4%) 32 (46%) 1 (1%) 4 (6%) 37 (54%) 11 (16%) 18 (26%) 14 (20%) 
  Present (10) 0 (0%) 4 (40%) 0 (0%) 0 (0%) 6 (60%) 3 (30%) 3 (30%) 2 (20%) 




















PTEN Loss & 
pAKT_High 
Ethnicity         
  Chinese (100) 11 (11%) 5 (5%) 7 (7%) 0 (0%) 79 (79%) 20 (20%) 54 (54%) 12 (12%) 
  Non-Chinese (16) 1 (6%) 0 (0%) 2 (13%) 1 (6%) 12 (75%) 5 (31%) 6 (38%) 3 (19%) 
Gender         
  Male (54) 7 (13%) 3 (6%) 3 (6%) 1 (2%) 41 (76%) 18 (33%) 21 (39%)* 12 (22%)* 
  Female (62) 5 (8%) 2 (3%) 6 (10%) 0 (0%) 50 (81%) 7 (11%) 39 (63%)* 3 (5%)* 
Age         
  <65 (57) 7 (12%) 3 (5%) 3 (5%) 1 (2%) 43 (75%) 12 (21%) 29 (51%) 6 (11%) 
  >65 (59) 5 (8%) 2 (3%) 6 (10%) 0 (0%) 48 (81%) 13 (22%) 31 (53%) 9 (15%) 
Site         
  Proximal colon (26) 2 (8%) 1 (4%) 3 (12%) 0 (0%) 17 (65%) 7 (27%) 11 (42%) 4 (15%) 
  Distal colon/rectal (90) 10 (11%) 4 (4%) 6 (7%) 1 (1%) 74 (82%) 18 (20%) 49 (54%) 11 (12%) 
Stage         
  I & II (54) 8 (15%) 1 (2%) 5 (9%) 1 (2%) 40 (74%) 14 (26%) 24 (44%) 7 (13%) 
  III & IV (62) 4 (6%) 4 (6%) 4 (6%) 0 (0%) 51 (82%) 11 (18%) 36 (58%) 8 (13%) 
Grade         
  Well/Moderate (102) 12 (12%) 5 (5%) 7 (7%) 1 (1%) 80 (78%) 22 (22%) 52 (51%) 14 (14%) 
  Poor (14) 0 (0%) 0 (0%) 2 (14%) 0 (0%) 11 (79%) 3 (21%) 8 (57%) 1 (7%) 
Tumour Size         
<4cm (51) 5 (10%) 0 (0%) 4 (8%) 0 (0%) 43 (84%) 9 (18%) 30 (59%) 6 (12%) 
>4cm (65) 7 (11%) 5 (8%) 5 (8%) 1 (2%) 48 (74%) 16 (25%) 30 (46%) 9 (14%) 
Perforation          
  Absent (111) 12 (11%) 5 (5%) 9 (8%) 1 (1%) 87 (78%) 25 (23%) 56 (50%) 15 (14%) 
  Present (5) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (80%) 0 (0%) 4 (80%) 0 (0%) 
Vascular invasion         
  Absent (99) 11 (11%) 3 (3%) 8 (8%) 1 (1%) 80 (81%) 23 (23%) 51 (52%) 14 (14%) 
  Present (17) 1 (6%) 2 (12%) 1 (6%) 0 (0%) 11 (65%) 2 (12%) 9 (53%) 1 (6%) 
Lymphatic invasion         
  Absent (102) 11 (11%) 4 (4%) 8 (8%) 1 (1%) 80 (78%) 24 (24%) 51 (50%) 15 (15%) 
  Present (14) 1 (7%) 1 (7%) 1 (7%) 0 (0%) 11 (79%) 1 (7%) 9 (64%) 0 (0%) 
Perineural invasion         
  Absent (111) 12 (11%) 5 (5%) 9 (8%) 1 (1%) 88 (79%) 25 (23%) 57 (51%) 15 (14%) 
  Present (5) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (60%) 0 (0%) 3 (60%) 0 (0%) 
* represent p value <0.05. 
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3.1.7 Associations with survival 
Survival analysis was performed in 59 GC and 86 CRC patients that did not 
receive chemotherapy. These were selected to allow the prognostic value of PI3K 
pathway aberrations to be assessed without the confounding influence of 
chemotherapy. The median survival time of these patients was 15 months (range 
1-131) for GC and 23 (range 0-141) months for CRC. The prognostic impact of 
clinicopathological features and PI3K pathway aberrations are shown for GC and 
CRC in Table 3.6 and Table 3.7, respectively. In GC, the features of tumour stage, 
intestinal subtype, perforation, lymphatic and perineural invasion were associated 
with worse survival, but none of the PI3K pathway aberrations showed prognostic 
significance. In CRC, tumour stage and the presence of vascular, lymphatic and 
perineural tumour invasion were associated with worse survival. PIK3CA 
amplification was also associated with worse survival in univariate analysis 
(HR=3.20, 95%CI=1.12-9.14, p=0.03) but failed to reach significance in 









Table 3.6. Prognostic significance of PI3K pathway aberrations and 
clinicopathological variables in GC patients treated with surgery alone 
(n=59). 
 
Parameter HR 95%CI P value 
    
Univariate survival analysis     
    
Clinicopathological Features    
Ethnicity (non-Chinese vs Chinese) 0.68 0.16-2.88 0.60 
Gender (female vs male) 1.07 0.40-2.85 0.89 
Age (≥69 vs <69) 1.67 0.74-3.76 0.21 
Stage (III & IV vs I & II) 4.77 1.80-12.61 <0.01 
Tubular differentiation (poor/NOS vs well/moderate) 2.43 0.92-6.37 0.07 
Lauren classification (Intestinal vs non-intestinal) 3.14 1.49-6.63 <0.01 
Tumour Size (≥4 vs <4) 2.26 1.00-5.08 0.05 
Perforation (yes vs no) 16.72 3.87-72.16 <0.01 
Lymphatic invasion (yes vs no) 2.65 1.20-5.84 0.02 
Perineural invasion (yes vs no) 4.21 1.79-9.91 <0.01 
H.pylori (yes vs no) 0.57 0.17-1.90 0.36 
    
PI3K pathway aberrations    
PIK3CA mutation (mutation vs wildtype) 0.05 0.00-1728.00 0.57 
PIK3CA amplification (amplification vs wildtype) 1.35 0.66-2.76 0.42 
PTEN deletion (deletion vs wildtype) 1.52 0.21-11.29 0.68 
PI3K overexpression (presence vs absence) 0.05 0.00-78.20 0.42 
PTEN (loss vs normal) 1.56 0.74-3.27 0.24 
pAKT overexpression (presence vs absence) 0.77 0.29-2.01 0.59 
    
Major PI3K pathway aberrations (combined analysis) 
PTEN only (presence vs absence) 1.24 0.56-2.73 0.60 
PIK3CA amplification & PTEN loss (presence vs absence) 1.00 0.38-2.64 >0.99 
    
Multivariate survival analysis    
    
Stage (III & IV vs I & II) 1.78 0.57-5.61 0.32 
Lauren classification (Intestinal vs non-intestinal) 2.63 1.13-6.10 0.03 
Perforation (yes vs no) 13.74 2.84-66.44 <0.01 
Lymphatic invasion (yes vs no) 1.16 0.42-3.20 0.77 
Perineural invasion (yes vs no) 2.24 0.70-7.19 0.18 
        
 








Table 3.7. Prognostic significance of PI3K pathway aberrations and 
clinicopathological variables in CRC patients treated with surgery alone 
(n=86).  
 
Parameter  HR 95%CI P value 
    
Univariate survival analysis       
        
Clinicopathological Features       
Ethnicity (non-Chinese vs Chinese) 0.61 0.22-1.73 0.35 
Gender (female vs male) 1.28 0.66-2.50 0.46 
Age (≥65 vs <65) 1.42 0.71-2.82 0.32 
Site (distal & rectal vs proximal) 1.36 0.60-3.11 0.46 
Stage (III & IV vs I & II) 5.07 2.54-10.13 <0.01 
Grade (poor vs well/moderate) 1.29 0.46-3.66 0.63 
Tumour Size (≥4 vs <4) 0.71 0.37-1.35 0.30 
Perforation (yes vs no) 1.76 0.54-5.75 0.35 
Vascular invasion (yes vs no) 2.58 1.06-6.28 0.04 
Lymphatic invasion (yes vs no) 4.06 1.64-10.06 <0.01 
Perineural invasion (yes vs no) 5.74 1.63-20.27 <0.01 
        
PI3K pathway aberrations       
PIK3CA mutation (mutation vs wildtype) 0.17 0.02-1.27 0.08 
PIK3CA amplification (amplification vs wildtype) 3.20 1.12-9.14 0.03 
PTEN deletion (deletion vs wildtype) 0.22 0.03-1.57 0.13 
PI3K High (presence vs absence) 0.05 0.00-2529 0.59 
PTEN (loss vs normal) 1.78 0.70-4.58 0.23 
pAKT High (presence vs absence) 0.74 0.29-1.90 0.53 
        
Major PI3K pathway aberrations (combined analysis)       
PTEN loss only (presence vs absence) 2.00 1.02-3.93 0.05 
PTEN loss & High pAKT (presence vs absence) 1.18 0.46-3.03 0.76 
        
Multivariate survival analysis        
        
Stage (III & IV vs I & II) 4.47 2.09-9.53 <0.01 
Vascular invasion (yes vs no) 0.79 0.28-2.22 0.66 
Lymphatic invasion (yes vs no) 1.47 0.56-3.88 0.43 
Perineural invasion (yes vs no) 3.43 0.82-14.4 0.09 
PIK3CA amplification (amplification vs wildtype) 2.75 0.90-8.41 0.08 
    
 












The entry of PI3K pathway inhibitors into clinical trials has generated a keen 
interest in identifying predictive biomarkers that can be used to select patients 
who are most likely to benefit. Numerous authors have suggested that PIK3CA 
mutation could be a useful biomarker, with several independent studies reporting 
an association with in-vitro drug sensitivity or clinical response (Table 3.8).  
The relatively low frequency of PIK3CA mutations, together with 
observed activity of PI3K inhibitors in PIK3CA wildtype tumour cells, has led to 
consideration of other factors as possible biomarkers. PTEN loss, PTEN mutation, 
KRAS mutation, HER2 amplification, BRAF mutation and elevated expression of 
phosphorylated AKT have all been associated with sensitivity and response to 
PI3K inhibitors (Table 3.8). However, the lack of reproducibility of these 
associations have also cast doubt about their potential utility as biomarkers. 
Nonetheless, several of these molecular features have been incorporated into 
clinical trials. For example, the recruitment of patients to trials BYL719 
(NCT01219699) and GSK2636771 (NCT01458067) is based on their tumours 




Table 3.8  Reported associations between candidate biomarkers of PI3K pathway inhibitors and sensitivity or response to PI3K pathway 
inhibitors. Red cells indicate a positive association, green cells indicate an inverse association and black cells indicate a observed lack of 
significant association. 
 































































































































































































































































































































Dan 2010 AS605240 p110γ multiple Cell lines 39
Garnett 2012 AZD6428 p110b multiple Cell lines 639
Walsh 2013 BEZ235 PI3K/mTOR Lymphoma Cell lines 60
Dan 2010 BEZ235 PI3K/mTOR multiple Cell lines 39
Garnett 2012 BEZ235 PI3K/mTOR multiple Cell lines 639
Brachmann 2009 BEZ235 PI3K/mTOR Breast Cell lines 18
Serra 2008 BEZ235 PI3K/mTOR Breast Cell lines 21
Lehmann 2011 BEZ235 PI3K/mTOR Breast Cell lines 30
Serra 2008 BEZ235 PI3K/mTOR Breast Xenografts 2
Brachmann 2009 BEZ235 PI3K/mTOR Breast Xenografts 3
Shoji 2012 BEZ235 PI3K/mTOR EndometrialCell lines 13
Shoji 2012 BEZ235 PI3K/mTOR EndometrialXenografts 2
Santiskulvong2011 BEZ235 PI3K/mTOR Ovarian Cell lines 18
Santiskulvong2011 BEZ235 PI3K/mTOR Ovarian Xenografts 1
Sanchez 2011 BGT226 PI3K/mTOR Breast Cell lines 13
Walsh 2013 BGT226 PI3K/mTOR Lymphoma Cell lines 60
Sanchez 2011 BKM120 Class I PI3K Breast Cell lines 13
Park 2012 BKM120 Class I PI3K Gastric Cell lines 11
Walsh 2013 BKM120 Class I PI3K Lymphoma Cell lines 60
Brana 2012 BYL719 p110α multiple Clinical 35
Tanaka 2011 CH5132799 PI3K multiple Cell lines 35
Tanaka 2011 CH5132799 PI3K multiple Xenografts 8
O'Brien 2010 GDC-0941 PI3K Breast Cell lines 54
O'Brien 2010 GDC-0941 PI3K Breast Xenografts 5
Spoerke 2012 GDC-0941 PI3K Lung Cell lines 29
Spoerke 2012 GDC-0941 PI3K Lung Xenografts 5
Dan 2010 GDC-0941 PI3K multiple Cell lines 39
Kweei 2012 GDC-0941 PI3K multiple Cell lines 60
Garnett 2012 GDC-0941 PI3K multiple Cell lines 639
Wallin 2011 GDC-0980 PI3K/mTOR multiple Cell lines 164
Wallin 2011 GDC-0980 PI3K/mTOR multiple Xenografts 20
Dan 2010 IC87114 p110σ multiple Cell lines 39
Dan 2010 LY294002 PI3K multiple Cell lines 39
Janku 2012 multiple mTOR, PI3K multiple Clinical 140
Dan 2010 PI-103 PI3K/mTOR multiple Cell lines 39
Dan 2010 PI3Kα inhibitor IVp110α multiple Cell lines 39
Dan 2010 PX-866 PI3K multiple Cell lines 39
Ihle 2009 PX-866 PI3K multiple Xenografts 13
Dan 2010 TGX221 p110β multiple Cell lines 39
Yu 2008 WAY-175 PI3K multiple Cell lines 11
Yu 2008 WAY-176 PI3K multiple Cell lines 11
Dan 2010 wortmannin PI3K/mTOR multiple Cell lines 39
Dan 2010 ZSTK474 PI3K multiple Cell lines 39
Dan 2010 ZSTK474 PI3K multiple Xenografts 24
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Since the frequencies of PI3K pathway aberrations represent an increasingly 
important consideration in the development of PI3K inhibitors, this study was 
undertaken to consolidate the available information on 6 prominent PI3K pathway 
aberrations in GC and CRC. Through meta-analysis of published results, I have 
been able to summarize the overall frequency of aberrations and to investigate 
differences according to ethnicity and cancer type (Figure 3.1). These results 
should provide useful benchmarks and insights for further assessment, similar to 
previous meta-analyses of other genetic alterations such as TP53 mutation (Soussi 
et al., 2006), KRAS mutation (Ren et al., 2012), EGFR mutations (Bria et al., 
2011), HER2 amplification (Chan et al., 2012) and microsatellite instability (Des 
Guetz et al., 2009). In addition, the collation of individual study data containing 
information about the assays used, threshold values and study populations (Table 
3.1) should facilitate further detailed investigation of individual PI3K pathway 
aberrations as potential biomarkers. 
 In the study of frequencies of PI3K pathway according to ethnicity, GC 
from East Asian patients notably showed lower frequencies of PIK3CA mutations 
and PTEN loss, but a higher frequency of PTEN deletion, compared to GC from 
Caucasian patients. PTEN loss was also more frequent in CRC from East Asian 
compared to Caucasian patients. Further confirmation of these findings could be 
important for understanding differences in the aetiology and biology of GC and 
CRC between Asian and Caucasian populations, as well as for the planning of 
clinical trials.  
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I caution however that with the exception of PIK3CA mutation, a high 
degree of study heterogeneity was observed in the current meta-analysis. 
Different methodologies are likely to explain much of the variation, as suggested 
by individual study data for PTEN deletion in GC (Table 3.1). The four East 
Asian studies were performed by semi-quantitative PCR or by capillary 
electrophoresis. These methods are likely to result in higher frequencies of 
aberration compared to the more conservative fluorescent in-situ hybridization 
method used in the single publication on Caucasian GC. The large variability in 
antibodies and staining conditions used to investigate PTEN loss probably also 
contributed to the wide range of reported frequencies for this aberration. The low 
study heterogeneity observed for PIK3CA mutation frequency indicates the 
differences between East Asians and Caucasians are real and could impact upon 
the results of clinical trials for PI3K inhibitors. 
Single laboratory analysis of the 6 PI3K pathway aberrations performed in 
this study allowed direct comparison between GC and CRC and revealed several 
new insights. At least one PI3K pathway aberration was observed in 86% of GC 
and in 90% of CRC, indicating a significant involvement of this pathway in the 
development of gastrointestinal cancers (Figure 3.3). A high degree of mutual 
exclusion of the aberrations was also observed, with a larger proportion of 
tumours having single rather than multiple aberrations (52% vs 35% for GC; 60% 
vs 29% for CRC). This was especially apparent for genetic aberrations, with only 
5% of cases showing concurrent changes. These results support the concept that 
single aberrations within the PI3K pathway are sufficient for hyperactivity, in a 
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manner akin to the sufficiency of either KRAS or BRAF mutations for MEK 
pathway activation.  
Using common analytical methods I observed significant differences 
between GC and CRC for the frequencies of PIK3CA amplification (46% vs 4%, 
respectively), PTEN deletion (1% vs 8%) and PTEN loss (54% vs 78%). This 
could reflect varying dependence of gastric and colorectal tissue on different 
components of the PI3K pathway. In both GC and CRC, the much lower 
frequency of PTEN deletion compared to loss of PTEN expression suggests that 
alternate mechanisms such as PTEN methylation and possibly also mutation 
contribute to the reduced expression.  
 In conclusion, this meta-analysis and single laboratory study found 
evidence for ethnic and cancer type differences in the frequencies of some PI3K 
aberrations in GC and CRC. Analysis of co-occurrence uncovered that aberrations 
in the PI3K pathway occur in a large majority of GC and CRC tumours in a 
primarily mutually exclusive pattern. A degree of irreproducibility in reported 
frequencies and associations, as well as a high degree of heterogeneity in 
analytical methods, were also apparent. This heterogeneity could be clearly 
viewed as confounding the identification of reliable markers of response to PI3K 
pathway inhibitors. Caution should also be taken in interpreting ethnic differences 
observed in this study, as ethnicity was inferred from the country of origin of 
study populations. In a prior meta-analysis of sufficient study numbers, I found 
exclusion of US and multinational trials did not affect observations of ethnic 
differences in patient outcomes (Loh et al., 2012). Nonetheless, the ethnic 
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heterogeneity of modern populations should be acknowledged and considered in 
interpreting observations of ethnic differences. Clarity in the field awaits further 
standardized and combined assessment of candidate PI3K response predictors in 
large, independent sample series and clinical trials. 
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4  Results: Identification of Potential Biomarkers using 
OncoCarta Analysis 
 
4.1.1 Correlation of mutation profiles with IC50 values of BSP-A 
For this study, BSP-A was used as a PI3K inhibitor to identify biomarkers of 
sensitivity as part of collaboration with Bayer Healthcare. I first screened a panel 
of GC and CRC cell lines for their sensitivity to BSP-A. BSP-A inhibited the 
proliferation of GC and CRC cell lines at concentration ranging from 18 nM to 
greater than 5000 nM (Figure 4.1). Among 34 GC and 14 CRC cell lines, 50% 
(24/48) had IC50 less than 1000 nM, 30% (14/48) had IC50 between 1000-5000 
nM and 20% (10/48) had IC50 more than 5000 nM. The median IC50 values of 
BSP-A for all cell lines were 987 nM. 
OncoCarta analysis was performed to identify 304 common hot-spot 
cancer mutations in 29 genes. Mutations of nine different genes (PIK3CA, KRAS, 
BRAF, CTNBB1, FBX4, FBXW7, TP53, KIT and MAP2K1) were identified in the 
GC and CRC cell lines (Table 4.1). Overall, cell lines with PIK3CA mutations 
were more sensitive to BSP-A than cell lines without PIK3CA mutations 
(p=0.001; Figure 4.1). There was no significant association between KRAS 
mutation and drug sensitivity in the cell lines. However, when the CRC cell lines 
were further divided into different types of KRAS mutation, KRAS (G12V) was 
significantly associated with higher IC50 values (p=0.004) compared to cell lines 
without KRAS (G12V) mutation.  Taken together, this provides evidence that 
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PIK3CA mutation could be used as biomarker for response to BSP-A in GC and 
CRC, while KRAS (G12V) mutation could be used as biomarkers for response to 
BSP-A in CRC only. 
Table 4.1. Mutation status of 36 GC and 14 CRC cell lines determined by 
OncoCarta analysis. 
Cell Lines Cancer Type Mutations 
AGS GC KRAS(G12D), CTNNB1(G34E), PIK3CA(E545A) 
AZ521 GC CTNNB1(S37F) 
CLS145 GC WT 
FU97 GC WT 
HGC27 GC PIK3CA(E542K) 
HS746T GC WT 
IM95 GC PIK3CA(E542K) 
IST1 GC WT 
KATOIII GC WT 
MKN1 GC FBX4 (S8R) 
MKN28 GC WT 
MKN45 GC WT 
MKN7 GC WT 
MKN74 GC KRAS(G12V) 
NCI-N87 GC WT 
NUGC2 GC KRAS(T58I), TP53(G245S) 
NUGC3 GC WT 
NUGC4 GC WT 
OCUM1 GC CTNNB1(S45C) 
RERF GC WT 
SCH GC WT 
SNU1 GC KRAS(G12D) 
SNU16 GC WT 
SNU5 GC WT 
TMK1 GC FBX4(S8R) 
YCC1 GC TP53(R175H) 
YCC10 GC PIK3CA(H1047R) 
YCC11 GC WT 
YCC16 GC KRAS(Q61H), PIK3CA(E545K), MAP2K1(Y134C) 
YCC17 GC BRAF(G596R), PIK3CA(E545K), TP53(R273H) 
YCC18 GC TP53(R273C) 
YCC19 GC KIT(D52N) 
YCC20 GC WT 
YCC3 GC FBX4(S8R), TP53(R175H) 
YCC6 GC WT 
YCC7 GC FBX4(S8R), TP53(R175H) 
   
CCK81 CRC PIK3CA(C420R), CTNNB1(T41A), FBXW7(R465C) 
COLO205 CRC BRAF(V600E) 
COLO320 CRC TP53(R248W) 
DLD1 CRC KRAS(G13D), PIK3CA(E545K) 
HCC56 CRC KRAS(G12V) 
HCT116 CRC KRAS(G13D), PIK3CA(H1047R), CTNNB1(S45P) 
HT29 CRC BRAF(V600E), TP53(R273H) 
LS513 CRC KRAS(G12D) 
RCM1 CRC KRAS(G12V) 
RKO CRC BRAF(V600E), PIK3CA(H1047R) 
SW403 CRC KRAS(G12V) 
SW480 CRC KRAS(G12V), TP53(R273H) 
SW620 CRC KRAS(G12V), TP53(R273H) 




Figure 4.1. IC50 values for BSP-A in 34 GC and 14 CRC cell lines. The IC50 values of PI3K inhibitors in the GC cell 
lines were obtained from the average value of three independent experiments. The IC50 values of PI3K inhibitors in the 
CRC cell lines were obtained from single experiment. Each experiment was performed in three technical replicates.  
Heatmap (top panel) represents the mutation status of selected genes in the cell lines. Green indicates absence of 
mutation and red indicates presence of mutation. The heatmap (bottom panel) represents subtypes of KRAS mutations 




4.1.2 Signal transduction of KRAS/PI3K/ERK pathway 
CRC cell lines with KRAS (G12V) mutations were resistant to BSP-A, suggesting 
that cells with this mutation are not addicted to the PI3K pathway and may 
depend on other pathways for survival. One such alternate pathway could be the 
ERK pathway, as it has been reported that mutant KRAS (G12V) interacts with 
Raf-1 and transduces signals mainly through the ERK pathway in NIH3T3 cells 
(Cespedes et al., 2006). Therefore, I sought to confirm whether CRC cell lines 
with KRAS (G12V) are resistant to PI3K inhibition due to their dependency on the 
ERK pathway. Colo320, LS513, SW403 and LOVO cell lines with different 
mutant KRAS genotypes were selected to further evaluate the impact of different 
oncogenic KRAS mutations in regulating the AKT and ERK pathway. These cell 
lines harboured wildtype EGFR, BRAF and PIK3CA status according to the 
Cosmic mutation database (http://cancer.sanger.ac.uk/cancergenome/projects/ 
cell_lines/). Their KRAS mutation status was confirmed by pyrosequencing, as 
shown in Figure 4.2.  
si-KRAS was used to study the effect of KRAS in regulating cell 
proliferation and downstream effectors. The CRC cell lines with mutant KRAS 
showed significant reduction in cell proliferation compared to the KRAS wildtype 
cell line Colo320 (Figure 4.3), suggesting they were dependent on KRAS for 
growth. In addition, knockdown of KRAS in SW403 (KRAS G12V) showed 
dramatically decreased pERK and slightly decreased in pAKT levels compared to 
Colo320, LS513 or LOVO cells (Figure 4.4). This result indicated that KRAS 
(G12V) transduces signals mainly through the ERK pathway, whereas wildtype 
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KRAS and other mutant form of KRAS (G12D or G13D) had minimal effect on the 





Figure 4.2. Pyrosequencing analysis of KRAS mutations in Colo320 (WT), 
LS513 (G12D), SW403 (G12V) and LOVO (G13D) cell lines. Pyrograms 
generated using the allele quantification (AQ) output for different cell lines as 
labeled. AQ was performed for the nucleotides within the yellow-shaded region. 
KRAS wildtype and three different KRAS mutations have been identified. (A) WT: 
codon 12: GGT; codon 13: GGC (B) G12D: codon 12: GAT; codon 13: GGC (C) 






Figure 4.3. Effect of KRAS knockdown on cell proliferation in CRC cell 
lines. Cell lines were silenced with 25nM of siRNA and MTS assay was 
performed at 72 hour. * indicates p<0.05. Data from two independent experiments 
performed in triplicate is shown.  
 
Figure 4.4. Protein expression levels of p-ERK (Thr202/Tyr204) and p-AKT 
(Ser473) after KRAS knockdown. Protein lysates were collected 48hr after 

















































































4.1.3 Response of CRC cell lines with different KRAS mutations to MEK and 
PI3K inhibitors 
As KRAS (G12V) appeared to transduce signals mainly through the ERK 
pathway, I therefore hypothesized this mutation could be more responsive to 
MEK inhibition compared to PI3K inhibition. Four of the CRC cell lines were 
further treated with the MEK and PI3K inhibitors BSP-C (Iverson et al., 2009) 
and BSP-A, respectively. As hypothesized, SW403 was sensitive to the MEK 
inhibitor but resistant to the PI3K inhibitor (Figure 4.5). This further confirmed 
the finding that SW403 is more dependent on the ERK signaling pathway than on 
the PI3K signaling pathway in the control of cell proliferation. 
 
Figure 4.5. IC50 values for BSP-A and BSP-C in CRC cell lines with different 
KRAS mutations. Results are derived from MTS assay performed at 72 h. * 







This work is the first to report on the drug sensitivity of PI3K inhibitors in a large 
panel of GC and CRC cell lines. The in vitro data showed that GC cell lines with 
PIK3CA mutations were particularly sensitive to BSP-A (Figure 4.1), indicating 
this genetic alteration is a predictive biomarker for PI3K inhibitors. Several 
studies have reported that PIK3CA with gain of function mutations promotes cell 
proliferation in vitro and in vivo (Samuels and Velculescu, 2004; Engelman et al., 
2008). In addition, MCF10A cells transfected with oncogenic PIK3CA mutants 
were sensitive to the classical PI3K inhibitor LY294002 compared with wildtype 
PIK3CA, suggesting that PIK3CA mutation could mediate PI3K addiction (Zhang 
et al., 2008).   
To date, it is still unclear whether KRAS mutations confer resistance to 
single agent PI3K inhibitors as there are conflicting results in the literature (Dan 
et al., 2010; Tanaka et al., 2011; Park et al., 2012). In this study, no significant 
association was found between KRAS mutation and sensitivity to BSP-A. 
However, new evidence has begun to highlight that a simple classification of 
KRAS mutant status may not be appropriate. De Roock and colleagues reported 
that primary CRC and CRC cell lines with different KRAS mutations exhibit 
different sensitivity to the anti-EGFR drug cetuximab (De Roock et al., 2010). 
Garassino et al. also found that different KRAS mutations were associated with 
different sensitivity to a number of chemotherapeutic agents in NSCLC 
(Garassino et al., 2011). Therefore, in the present study KRAS mutations were 
stratified into different types and investigated for associations with drug 
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sensitivity. Interestingly, KRAS (G12V) was associated with resistance to PI3K 
inhibitors in CRC cell lines (Figure 4.1). It was reported previously that KRAS 
(G12V) transduces signals mainly through the ERK rather than PI3K pathway in 
mouse fibroblasts (Cespedes et al., 2006). To confirm this finding in CRC, KRAS 
was knocked down in cell lines having different KRAS mutations. Cells with 
KRAS (G12V) showed a large decrease in pERK, but not cell lines with wildtype 
or other KRAS mutation types (G12D/G13D) (Figure 4.4). The dependency of 
KRAS (G12V) mutant cell lines on the ERK pathway may explain their reduced 
dependence on the PI3K pathway. Moreover, this study showed the SW403 cell 
line harbouring KRAS (G12V) was sensitive to MEK inhibition (Figure 4.5). This 
suggests that different KRAS mutations could have non-synonymous functional 
activities, thus leading to different outcomes in patients treated with PI3K 
inhibitors.   
It was shown here that KRAS (G12V) cells were more dependent on ERK 
signaling than on PI3K signaling (Figure 4.4). This may explain why CRC cell 
lines with KRAS (G12V) mutation were observed to be more resistant to PI3K 
inhibitor than other KRAS mutant cell lines. It also suggests that inhibition of 
PI3K signaling may be useful in patients with KRAS (G12D) or KRAS (G13D) 
mutant tumours. However, the observation was made in a small number of CRC 
cell lines (n=14) and only one cell line with KRAS (G12V) mutation was used to 
dissect the downstream signalling of mutant KRAS. Hence, greater numbers of 
cell lines are needed to confirm the findings and also to further investigate 
whether other cancer types with the KRAS (G12V) mutation show similar 
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behavior. Moreover, isogenic cell line models which haboured different KRAS 
mutations may help to confirm this finding. The results obtained could have 




5 Results: Identification of Potential Biomarkers in PIK3CA 
Wildtype GC Cell Lines using RNA-sequencing  
 
5.1.1 Sensitivity of PI3K inhibitors in 8 GC cell lines with PIK3CA wildtype 
background 
My results presented in Chapter 4 showed that the cell lines with PIK3CA 
mutation were more sensitive to PI3K inhibitors than cell lines without PIK3CA 
mutations. However, some PIK3CA wildtype cells also were sensitive to these 
inhibitors. To identify biomarkers in GC cell lines with wildtype PIK3CA, I 
decided to make use of RNA-sequencing technology. I selected 8 PIK3CA 
wildtype cells (Kato3, MKN28, NUGC3, NUGC4, SNU5, YCC1, YCC11 and 
HS746T) to identify other factors that can determine sensitivity to PI3K 
inhibitors. The RNA-sequencing analysis was performed in 8 cell lines only and 
there were no technical replicates performed due to cost constraints.  These GC 
cell lines were wildtype in all the 29 genes tested by OncoCarta, except YCC1 
which haboured a p53 (R175H) mutation (Table 4.1). In addition to BSP-A, other 
PI3K inhibitors (BSP-B, BKM120, GDC-0941, BYL719 and XL147) were 
included for IC50 screening of all GC cell lines to ensure the observations were 





Table 5.1. IC50 values (nM) ± standard deviation for PI3K inhibitors in 8 GC 
cell lines. The IC50 values of PI3K inhibitors in the GC cell lines were obtained 
from the average value of three independent experiments. Each experiment was 
performed in three technical replicates.   
 
Cell lines BSP-A BSP-B GDC-0941 BKM120 BYL719 XL147 
HS746T 1155±200 >5000 >10000 3576±178 >10000 >10000 
Kato3 1125±746 >5000 >10000 5612±959 >10000 9644±504 
MKN28 2090±1365 >5000 >10000 3615±872 >10000 >10000 
NUGC3 230±163 3301±1110 2661±2041 3068±1339 >10000 >10000 
NUGC4 336±88 >5000 2121±1915 1583±976 >10000 >10000 
SNU5 522±446 >5000 5402±4219 909±581 >10000 >10000 
YCC1 193±181 945±119 1133±703 2288±1266 3014±885 >10000 
YCC11 376±103 >5000 2755±1610 1950±381 8713±1383 >10000 
 
 
To further classify the cell lines into sensitive and resistant groups, unsupervised 
clustering was performed using quantile normalized IC50 values. As shown in 
Figure 5.1, two major clusters were observed where NUGC3, NUGC4, SNU5, 
YCC1 and YCC11 were classified as sensitive group, whereas Kato3, MKN28 
and HS746T were classified as resistant group.  
 
Figure 5.1. Unsupervised clustering of 8 GC cell lines based on quantile 
normalized IC50 values of PI3K inhibitors.  
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5.1.2 Correlation between IC50 values of PI3K inhibitors and the gene 
expression profile of 8 GC cell lines 
The assessment of RNA integrity is a critical first step in obtaining meaningful 
gene expression data. All samples had a RIN>8, and their cDNA libraries for 
RNA-sequencing were prepared thereafter. Quality analysis of the libraries was 
performed using the Agilent Bioanalyzer and results are displayed in Appendix 
Figure 1. The majority of cDNA was fragmented in the range of 200-500 bp, 
which is the optimal size for the subsequent sequencing step. RNA sequencing 
was completed successfully for all samples (Appendix Table 1), with an average 
of 66 million reads per sample obtained. Median quality scores for all reads across 
all samples were more than 28, as shown in the per base sequence quality plot 
(Appendix Figure 2), suggesting good quality reads. To better understand the 
cellular pathways involved with resistance to PI3K inhibition, differential 
expressed gene transcripts between sensitive and resistant cell lines was analysed 
by ANOVA using Partek software. Volcano plot as shown in Figure 5.2 displayed 
the distribution of p-value and fold-change of individual transcript. ANOVA 
analysis revealed 617 transcripts were differentially expressed at least by 1.5 fold 
with p<0.05 (Table 5.2). These comprised of 258 transcripts that were up-
regulated and 359 that were down-regulated in the sensitive cell lines. IGFBP3, 
one of the major upstream activators of the PI3K pathway, exhibited the highest 






Figure 5.2. Fold change and p-value of different transcripts between sensitive 











Table 5.2. Genes differentially expressed between cell lines sensitive and 
resistant to PI3K inhibitors according to RNA Sequencing Analysis. The 
candidates are filtered for fold change greater than 1.5 with p<0.05, and sorted 
according to fold change.  
 
Gene Symbol Transcript p-value Fold-Change 
IGFBP3 NM_001013398 0.000 67.429 
IGFBP3 NM_000598 0.001 54.785 
PDK4 NM_002612 0.045 26.210 
DNAJC15 NM_013238 0.000 17.650 
RPL36 NM_033643 0.020 16.398 
ID1 NM_181353 0.008 14.085 
PECR NM_018441 0.018 12.644 
HOXA10 NR_037939 0.002 12.348 
NUP210 NM_024923 0.001 11.201 
IAH1 NM_001039613 0.016 10.625 
CYP51A1 NM_000786 0.018 10.436 
ZNF32 NM_006973 0.003 10.386 
HHEX NM_002729 0.002 10.124 
KBTBD7 NM_032138 0.009 7.605 
NETO2 NM_001201477 0.039 7.247 
FOXC1 NM_001453 0.040 7.151 
HNMT NM_006895 0.037 7.070 
ALDH3B1 NM_001030010 0.022 6.909 
HOXA13 NM_000522 0.006 6.667 
FAM213A NM_032333 0.040 6.379 
SLC25A4 NM_001151 0.000 6.189 
FAM127B NM_001134321 0.006 6.174 
LONRF2 NM_198461 0.022 5.944 
PRKAG1 NM_002733 0.027 5.903 
NETO2 NM_018092 0.045 5.839 
ZIC5 NM_033132 0.037 5.831 
DHRS3 NM_004753 0.046 5.735 
SNORA45A NR_002580 0.011 5.669 
TRAPPC3 NR_073098 0.033 5.635 
HOMER2 NM_199330 0.014 5.629 
RNASE4 NM_194431 0.019 5.555 
TP53TG1 NR_015381 0.000 5.545 
LINC00997 NR_036501 0.015 5.493 
SNORD76 NR_003942 0.003 5.455 
MGST2 NM_001204368 0.046 5.447 
FAM213A NM_001243781 0.036 5.435 
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C9orf16 NM_024112 0.037 5.319 
FAM213A NM_001243778 0.038 5.256 
SNORA18 NR_002959 0.033 5.208 
SNORA14B NR_002956 0.000 5.133 
GPR137B NM_003272 0.000 4.922 
LAMTOR2 NM_014017 0.007 4.710 
SNORA43 NR_002975 0.035 4.591 
POLD2 NM_006230 0.043 4.561 
SNORD89 NR_003070 0.010 4.551 
ZNF606 NM_025027 0.050 4.479 
RPLP0 NM_001002 0.024 4.448 
FAM213A NM_001243782 0.029 4.423 
ZIC2 NM_007129 0.018 4.372 
NUP62CL NM_017681 0.025 4.361 
SNORD8 NR_002916 0.011 4.355 
OS9 NM_006812 0.019 4.232 
SLC2A6 NM_001145099 0.000 4.184 
RNPS1 NM_001286627 0.012 4.093 
PAX8-AS1 NR_047570 0.019 4.089 
SNORD94 NR_004378 0.046 4.009 
ZNF480 NM_001297624 0.050 3.992 
CARHSP1 NM_001042476 0.005 3.978 
ASPHD1 NM_181718 0.034 3.966 
PARVB NM_001243386 0.027 3.955 
ANKRD16 NM_019046 0.001 3.914 
SNORA62 NR_002324 0.010 3.850 
RNU4ATAC NR_023343 0.045 3.845 
OPN3 NM_014322 0.036 3.834 
RPL17 NM_001199341 0.016 3.827 
TP53 NM_001126115 0.004 3.795 
TP53 NM_001276697 0.004 3.795 
HCFC1R1 NM_001288666 0.008 3.794 
SPIN3 NM_001010862 0.034 3.772 
POLD4 NR_046411 0.040 3.767 
HIST1H2BD NM_138720 0.014 3.754 
LOC100652758 NM_001278082 0.039 3.703 
ACADM NM_001286042 0.023 3.699 
HSPA4L NM_014278 0.035 3.699 
ZFP3 NM_153018 0.044 3.653 
SNORD9 NR_003029 0.048 3.634 
ANXA2R NM_001014279 0.031 3.589 
SNORA52 NR_002585 0.006 3.532 
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CDNF NM_001029954 0.023 3.471 
MPC2 NR_026550 0.026 3.446 
SLC22A3 NM_021977 0.043 3.408 
SESTD1 NM_178123 0.043 3.365 
NEO1 NM_001172624 0.001 3.350 
SCARNA11 NR_003012 0.029 3.279 
COX5B NM_001862 0.022 3.272 
IRAK1BP1 NM_001010844 0.049 3.240 
RNU6ATAC NR_023344 0.024 3.188 
RPL31P11 NR_002595 0.007 3.154 
TRIQK NM_001191036 0.020 3.144 
MTERF1 NM_001301134 0.016 3.114 
MTERF1 NM_006980 0.016 3.111 
RPL18 NM_001270490 0.018 3.110 
CRAT NM_000755 0.012 3.096 
SNORA10 NR_002327 0.048 3.079 
SNORA38B NR_003706 0.005 3.078 
FAM117B NM_173511 0.049 3.071 
TMEM17 NM_198276 0.031 3.060 
TSPAN31 NM_005981 0.023 3.060 
ENKD1 NM_032140 0.010 3.054 
ZNF32 NM_001005368 0.027 3.044 
PIK3R3 NM_003629 0.002 3.044 
NTPCR NM_032324 0.017 3.043 
SEZ6L2 NM_001243333 0.001 3.042 
LOC100132352 NR_034006 0.002 3.039 
RNASEL NM_021133 0.005 3.034 
PCED1A NM_022760 0.024 3.012 
CACYBP NM_001007214 0.022 2.994 
STAT3 NM_213662 0.003 2.983 
ST6GALNAC4 NM_175040 0.042 2.965 
CCNG1 NM_199246 0.011 2.965 
SNORA34 NR_002968 0.043 2.957 
SNORA9 NR_002952 0.029 2.919 
LSS NM_001145437 0.040 2.918 
UBE2D4 NM_015983 0.033 2.916 
FAHD2A NM_016044 0.021 2.902 
SEMA3B NM_001290061 0.037 2.895 
PDCD6 NM_013232 0.048 2.873 
KIAA0895 NM_015314 0.039 2.871 
TM2D2 NM_078473 0.010 2.871 
NEO1 NM_002499 0.000 2.868 
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GGA1 NM_001172688 0.002 2.807 
ARAP1 NM_015242 0.042 2.794 
SNORA20 NR_002960 0.039 2.756 
VMAC NM_001017921 0.020 2.737 
RBM26 NM_001286632 0.043 2.728 
SNORA21 NR_002576 0.022 2.720 
MMAA NM_172250 0.015 2.713 
BBS1 NM_024649 0.039 2.686 
PAIP2 NM_001033112 0.048 2.685 
TTC14 NM_001288582 0.015 2.679 
TTC14 NM_001042601 0.035 2.671 
SNORD97 NR_004403 0.030 2.669 
PON2 NM_001018161 0.010 2.648 
RRNAD1 NM_015997 0.016 2.646 
TMLHE NM_001184797 0.000 2.638 
KRT8 NR_045962 0.023 2.586 
PHKB NM_000293 0.046 2.548 
SNORA8 NR_002920 0.013 2.547 
SNORA24 NR_002963 0.008 2.546 
SCYL3 NM_020423 0.011 2.508 
TSEN34 NM_024075 0.011 2.494 
UFC1 NM_016406 0.042 2.489 
SNORA31 NR_002967 0.049 2.480 
LINC00263 NR_026762 0.023 2.477 
L3HYPDH NM_144581 0.034 2.450 
TMEM161B-AS1 NR_105019 0.007 2.437 
TAPT1-AS1 NR_027696 0.044 2.431 
PDCD6 NM_001267558 0.026 2.413 
ATP6V0E2 NM_001100592 0.013 2.411 
ZNF717 NM_001290210 0.036 2.406 
SCARNA13 NR_003002 0.043 2.396 
SEZ6L2 NM_201575 0.031 2.393 
TIMP1 NM_003254 0.020 2.383 
HMBOX1 NM_001135726 0.045 2.364 
IFT140 NM_014714 0.032 2.364 
GMPR2 NM_001002002 0.048 2.364 
ARV1 NM_022786 0.047 2.359 
GALK2 NM_002044 0.038 2.334 
LRRC37A6P NR_003525 0.021 2.332 
NRIP1 NM_003489 0.038 2.325 
ZNF669 NM_024804 0.000 2.322 
ANKRD9 NM_152326 0.037 2.307 
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FUT10 NM_032664 0.044 2.290 
SELO NM_031454 0.027 2.282 
GRAMD1B NM_020716 0.044 2.275 
IFITM3 NM_021034 0.025 2.265 
TRMT1L NM_001202423 0.013 2.261 
SNORA48 NR_002918 0.038 2.252 
UBAP2L NM_001287815 0.027 2.241 
SNORA70 NR_000011 0.039 2.231 
FAM213A NM_001243780 0.033 2.202 
TPT1 NM_003295 0.024 2.199 
MOSPD3 NM_023948 0.033 2.191 
FASTKD1 NR_104020 0.019 2.179 
CEBPZOS NR_037879 0.046 2.157 
TPCN1 NM_017901 0.017 2.154 
GRAMD1B NM_001286563 0.040 2.136 
FBXL19-AS1 NR_024348 0.025 2.132 
C1RL NM_001297642 0.039 2.119 
POLR1B NM_001282776 0.042 2.117 
MTX2 NR_027850 0.045 2.106 
RAB12 NM_001025300 0.022 2.097 
PPIA NM_021130 0.041 2.095 
DUSP19 NM_001142314 0.047 2.090 
FRAT1 NM_005479 0.028 2.069 
ABCA2 NM_001606 0.021 2.061 
TBCE NM_001287802 0.025 2.047 
SNORA71C NR_003017 0.001 2.042 
FAM89B NM_001098784 0.049 2.035 
ZNF213-AS1 NR_110900 0.031 2.033 
MTIF3 NM_001166261 0.009 2.016 
REL NM_002908 0.022 2.013 
CCDC22 NM_014008 0.020 2.008 
SIRT5 NM_001242827 0.008 2.001 
RPL7A NM_000972 0.044 1.998 
MPHOSPH9 NR_103517 0.024 1.972 
MTR NM_001291939 0.009 1.966 
REL NM_001291746 0.021 1.963 
PRKAA1 NM_006251 0.020 1.945 
PRKAA1 NM_206907 0.020 1.944 
ATP6V0A1 NM_005177 0.037 1.944 
ATP6V0A1 NM_001130021 0.037 1.944 
CNIH4 NR_102347 0.049 1.940 
TLCD1 NM_001160407 0.022 1.932 
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NFU1 NM_001002756 0.016 1.922 
USP15 NM_001252079 0.044 1.910 
CDK13 NM_031267 0.040 1.895 
ABCA2 NM_212533 0.024 1.884 
SLC10A7 NM_001029998 0.024 1.877 
EXOC8 NM_175876 0.031 1.857 
RPS15A NM_001030009 0.025 1.851 
UBL5 NM_024292 0.030 1.841 
PSME1 NM_176783 0.011 1.833 
HSPA1L NM_005527.2 0.040 1.823 
SURF4 NM_001280792 0.025 1.822 
SPG7 NM_003119 0.024 1.821 
TNIP1 NM_001258456 0.049 1.810 
RPL17-C18orf32 NM_001199355 0.047 1.810 
SNORD10 NR_002604 0.038 1.809 
STAT3 NM_139276 0.021 1.798 
RPS24 NM_033022 0.005 1.794 
RPS24 NM_001142284 0.005 1.793 
RPS24 NM_001142283 0.005 1.793 
ZNHIT1 NM_006349 0.032 1.761 
ZFC3H1 NM_144982 0.028 1.760 
ALKBH7 NM_032306 0.008 1.756 
BTBD2 NM_017797 0.014 1.753 
HFE NM_001300749 0.023 1.749 
MAN1B1 NR_045721 0.024 1.744 
PCSK6 NM_001291309 0.046 1.728 
SPIN3 NR_027139 0.032 1.727 
RALGDS NM_006266 0.043 1.708 
OGDH NM_001003941 0.042 1.708 
DNASE1L1 NM_001009932 0.036 1.703 
RPS15 NM_001018 0.014 1.700 
HGSNAT NM_152419 0.001 1.689 
RPS24 NM_001026 0.008 1.684 
RPRD2 NM_001297674 0.037 1.680 
RPRD2 NM_015203 0.036 1.680 
R3HDM2 NM_014925 0.026 1.678 
APBA3 NM_004886 0.031 1.678 
TOR1AIP1 NM_015602 0.024 1.669 
TOR1AIP1 NM_001267578 0.024 1.669 
TOMM20 NM_014765 0.019 1.664 
H2AFY NM_138609 0.002 1.649 
CUX1 NM_001202544 0.041 1.647 
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CUX1 NM_001913 0.041 1.646 
USP20 NM_006676 0.008 1.640 
PRMT2 NM_001242866 0.040 1.627 
TUBB4B NM_006088 0.048 1.621 
GDE1 NM_016641 0.041 1.615 
CCDC112 NM_152549 0.040 1.597 
DCAF11 NR_028099 0.012 1.596 
RPL13 NM_033251 0.037 1.573 
SNRNP200 NM_014014 0.015 1.568 
RPL13AP20 NR_003932 0.002 1.568 
PSME2 NM_002818 0.028 1.553 
UQCRHL NM_001089591 0.032 1.522 
ALKBH1 NM_006020 0.009 -1.506 
FAM35DP NR_027634 0.035 -1.512 
WBP11P1 NR_003558 0.005 -1.515 
SDCBP2-AS1 NR_040049 0.043 -1.519 
RORA NM_134261 0.045 -1.522 
SSR3 NM_007107 0.045 -1.524 
SATB2 NM_015265 0.034 -1.537 
IGDCC4 NM_020962 0.035 -1.540 
ZBTB2 NM_020861 0.001 -1.541 
PRKAR1B NM_001164760 0.038 -1.546 
ATN1 NM_001940 0.045 -1.547 
ATN1 NM_001007026 0.045 -1.547 
ATF2 NR_045769 0.004 -1.550 
MRPL1 NM_020236 0.046 -1.553 
WDR53 NM_182627 0.008 -1.553 
RAET1G NM_001001788 0.048 -1.554 
PSMD12 NM_002816 0.007 -1.556 
NR1D2 NR_110524 0.028 -1.561 
NR1D2 NM_005126 0.028 -1.561 
PPARD NM_001171819 0.038 -1.566 
NR1D2 NM_001145425 0.042 -1.570 
CRELD2 NM_024324 0.020 -1.572 
TM2D2 NM_031940 0.048 -1.574 
FAM198B NM_001031700 0.036 -1.574 
TTC19 NM_001271420 0.004 -1.576 
UBXN2A NM_181713 0.008 -1.582 
INPP5A NM_005539 0.031 -1.589 
CFAP70 NM_145170 0.043 -1.591 
NFYB NM_006166 0.048 -1.592 
ATP6V1C1 NM_001695 0.020 -1.594 
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KANSL1 NM_015443.1 0.036 -1.595 
PTBP2 NR_125357 0.029 -1.605 
TMED8 NM_213601 0.036 -1.605 
FAM133A NM_173698 0.036 -1.609 
AKAP17A NR_027383.1 0.031 -1.611 
AKAP17A NM_005088 0.031 -1.612 
ATP13A3 NM_024524 0.046 -1.613 
CEP44 NM_001145314 0.044 -1.618 
NFATC2 NM_001258297 0.050 -1.622 
ZNF212 NM_012256 0.044 -1.627 
DGKZ NM_001199266 0.038 -1.630 
TCEB1 NM_001204861 0.048 -1.633 
USP1 NM_001017415 0.040 -1.638 
RALGAPB NM_001282917 0.025 -1.654 
RALGAPB NM_001282918 0.038 -1.655 
DAAM1 NM_014992 0.011 -1.656 
ZNF609 NM_015042 0.002 -1.657 
UBE2J2 NM_194457 0.022 -1.657 
CASP7 NM_033340 0.007 -1.660 
NOLC1 NM_001284388 0.025 -1.662 
EPS15 NM_001981 0.029 -1.670 
ADAM15 NM_207195 0.040 -1.671 
FOXK2 NM_004514 0.047 -1.673 
EFR3A NM_015137 0.025 -1.674 
ZNF98 NM_001098626 0.045 -1.674 
VEPH1 NM_001167917 0.047 -1.675 
MEF2A NM_005587 0.036 -1.676 
BTF3L4 NM_001243767 0.042 -1.678 
TWISTNB NM_001002926 0.036 -1.679 
NHLRC2 NM_198514 0.033 -1.681 
DNAJC9 NM_015190 0.017 -1.700 
ZXDC NM_001040653 0.039 -1.707 
DNMT3B NM_001207055 0.037 -1.707 
BAIAP2 NM_001144888 0.047 -1.708 
MED6 NM_005466 0.030 -1.712 
DCAF13P3 NR_027642 0.028 -1.718 
PIGA NR_033836 0.044 -1.721 
GGA1 NM_013365 0.036 -1.744 
DHX33 NM_001199699 0.023 -1.744 
HEMK1 NM_016173 0.038 -1.747 
USP1 NM_001017416 0.015 -1.749 
MAP4K5 NM_198794 0.044 -1.750 
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PABPC4 NM_003819 0.013 -1.753 
MINA NM_153182 0.017 -1.753 
LDB1 NM_003893 0.044 -1.757 
FAM193A NR_046335 0.040 -1.758 
HNRNPR NM_001297622 0.016 -1.758 
ZDHHC6 NM_022494 0.044 -1.761 
RABEP1 NM_004703 0.040 -1.769 
TBC1D23 NM_001199198 0.029 -1.770 
TBC1D23 NM_018309 0.029 -1.770 
TMEM51 NM_001136218 0.003 -1.773 
CTC1 NM_025099 0.041 -1.785 
HNRNPR NM_001297621 0.043 -1.788 
MINA NM_001261829 0.020 -1.789 
FLCN NM_144997 0.004 -1.793 
NUF2 NM_031423 0.034 -1.796 
POFUT1 NM_015352 0.048 -1.796 
DNMT1 NM_001130823 0.042 -1.798 
CLASP2 NM_015097 0.021 -1.802 
RFC1 NM_001204747 0.046 -1.804 
SLC25A32 NM_030780 0.024 -1.804 
RABEP1 NM_001083585 0.032 -1.805 
PVR NM_001135768 0.047 -1.805 
PVR NM_001135769 0.047 -1.805 
ATXN3 NR_028458 0.032 -1.807 
TTC29 NM_031956 0.000 -1.817 
C2CD2L NM_001290474 0.041 -1.818 
RFC1 NM_002913 0.019 -1.824 
MKRN2 NM_001271707 0.012 -1.825 
SLC25A32 NR_102337 0.010 -1.827 
SLC35B3 NR_109914 0.031 -1.828 
CYB561D1 NM_001134404 0.049 -1.829 
MEF2A NM_001171894 0.048 -1.830 
PTER NM_001261838 0.037 -1.839 
VPS16 NM_022575 0.032 -1.845 
MRTO4 NM_016183 0.022 -1.850 
CBWD1 NM_001145355 0.007 -1.850 
TMEM181 NM_020823 0.042 -1.858 
SAAL1 NM_138421 0.047 -1.860 
C11orf45 NM_001256088 0.043 -1.865 
SMNDC1 NM_005871 0.045 -1.875 
ANKRD11 NM_013275 0.020 -1.880 
ANKRD11 NM_001256182 0.020 -1.881 
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STX18 NM_016930 0.006 -1.893 
RREB1 NM_001003699 0.023 -1.897 
NCOA1 NM_003743 0.044 -1.898 
MAPK7 NM_002749 0.000 -1.902 
CENPO NM_024322 0.008 -1.904 
LOXL1-AS1 NR_040068 0.050 -1.920 
KIAA1598 NM_018330 0.003 -1.922 
ZSCAN9 NM_001199480 0.001 -1.928 
LINC01426 NR_038886 0.035 -1.934 
MEF2A NM_001130928 0.031 -1.941 
ZNF821 NM_001201556 0.045 -1.941 
SPECC1L NM_001254732 0.005 -1.942 
TTPAL NM_001261839 0.013 -1.946 
CCDC186 NM_018017 0.031 -1.953 
ZBTB38 NM_001080412 0.010 -1.959 
SEC14L1 NM_003003 0.023 -1.961 
UAP1L1 NM_207309 0.040 -1.964 
MTFR2 NM_001099286 0.016 -1.968 
MICAL3 NM_001136004 0.013 -1.969 
POLE3 NR_027261 0.043 -1.970 
NR2F2 NM_001145157 0.043 -1.970 
FOXO3 NM_201559 0.007 -1.975 
LMLN NR_026786 0.000 -1.975 
SHOC2 NM_007373 0.009 -1.980 
ATL2 NR_024191 0.032 -1.984 
ATPAF1 NM_022745 0.013 -1.993 
YAP1 NM_001130145 0.022 -1.994 
YAP1 NM_001195044 0.022 -1.995 
RNF38 NM_022781 0.044 -2.002 
RBL1 NM_002895 0.030 -2.006 
MTMR14 NM_022485 0.025 -2.006 
BAHD1 NM_014952 0.018 -2.013 
SPECC1L NM_001145468 0.012 -2.019 
YAP1 NM_001282097 0.013 -2.022 
C11orf45 NR_045767 0.000 -2.023 
YAP1 NM_006106 0.013 -2.023 
SCO2 NM_005138 0.040 -2.024 
SNORA58 NR_002985 0.001 -2.030 
EPN2 NM_014964 0.029 -2.030 
CTBP2 NM_001290214 0.048 -2.033 
PRIMPOL NM_152683 0.031 -2.034 
THAP7 NM_001008695 0.047 -2.043 
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ATG5 NM_001286106 0.022 -2.047 
RAPGEF2 NM_014247 0.025 -2.047 
GABPB1 NM_005254 0.019 -2.048 
GAR1 NM_032993 0.046 -2.050 
MFI2-AS1 NR_038285 0.006 -2.053 
ANKRD11 NM_001256183 0.009 -2.053 
ANAPC13 NM_001242374 0.035 -2.055 
CDK5RAP1 NM_016082 0.021 -2.059 
FOXJ2 NM_018416 0.006 -2.061 
ZCCHC17 NM_001282571 0.018 -2.064 
YAP1 NM_001282101 0.008 -2.065 
WHSC1 NM_133335 0.016 -2.065 
YAP1 NM_001282100 0.008 -2.066 
RYBP NM_012234 0.002 -2.072 
SORBS1 NM_006434 0.019 -2.081 
LINC00857 NR_038464 0.046 -2.082 
BOP1 NM_015201 0.026 -2.084 
SNAP29 NM_004782 0.017 -2.085 
ZNF367 NM_153695 0.018 -2.091 
NAGK NM_017567 0.012 -2.096 
PXK NM_001289096 0.001 -2.100 
PRIMPOL NM_001300768 0.046 -2.108 
EPG5 NM_020964 0.050 -2.112 
ASCC1 NM_001198799 0.027 -2.114 
SEPT8 NM_001098812 0.018 -2.124 
GBF1 NM_004193 0.007 -2.125 
YAP1 NM_001282099 0.007 -2.126 
YAP1 NM_001282098 0.007 -2.126 
RFC5 NM_181578 0.000 -2.141 
PUS1 NM_025215 0.008 -2.147 
TOP3A NM_004618 0.024 -2.155 
CAMTA2 NM_001171166 0.007 -2.157 
SLC23A2 NM_203327 0.038 -2.160 
CDC7 NM_001134419 0.032 -2.167 
DGCR11 NR_024157 0.009 -2.177 
CNBP NM_001127192 0.007 -2.182 
PPP1R8 NM_138558 0.009 -2.182 
MED8 NM_201542 0.022 -2.184 
PANX1 NM_015368 0.046 -2.186 
RTN4 NM_020532 0.026 -2.193 
ANAPC15 NM_001278494 0.005 -2.195 
KLC1 NM_001130107 0.005 -2.195 
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NRBF2 NM_001282405 0.022 -2.196 
IPPK NM_022755 0.028 -2.199 
PPRC1 NM_015062 0.028 -2.202 
LINC00152 NR_024204 0.010 -2.203 
MOV10 NM_001286072 0.020 -2.204 
CENPP NM_001286971 0.022 -2.204 
PDRG1 NM_030815 0.043 -2.207 
ARHGAP39 NM_025251 0.009 -2.212 
S1PR2 NM_004230 0.029 -2.213 
CSK NM_004383 0.020 -2.229 
NCOA1 NM_147233 0.002 -2.232 
SGPL1 NM_003901 0.030 -2.238 
RAB27A NM_183236 0.025 -2.250 
LYAR NM_001145725 0.006 -2.261 
PGS1 NR_110602 0.037 -2.262 
AIFM2 NM_001198696 0.023 -2.264 
SMC3 NM_005445 0.042 -2.273 
TMEM64 NM_001008495 0.035 -2.277 
TTC4 NM_004623 0.023 -2.282 
TRMT2A NM_001257994 0.034 -2.300 
DCLRE1B NM_022836 0.017 -2.300 
RAB27A NM_183235 0.024 -2.303 
USP1 NM_003368 0.021 -2.315 
TRIM6 NM_001003818 0.038 -2.316 
IPMK NM_152230 0.003 -2.323 
ZNF710 NM_198526 0.005 -2.324 
BCL2L13 NR_073068 0.015 -2.330 
CCNJ NM_001134376 0.045 -2.344 
PTGES2 NM_001256335 0.008 -2.345 
CTBP2 NM_001329 0.035 -2.364 
PSMB6 NM_002798 0.000 -2.371 
RUNX1-IT1 NR_026812 0.035 -2.376 
TTPAL NM_024331 0.010 -2.380 
TTPAL NM_001039199 0.010 -2.380 
LOC103344931 NR_120684 0.030 -2.381 
IFNLR1 NM_173065 0.041 -2.390 
PIGG NM_001289053 0.012 -2.399 
C10orf12 NM_015652 0.007 -2.403 
PTBP2 NM_001300990 0.015 -2.413 
SLC25A14 NM_001282195 0.004 -2.417 
MFSD2A NR_109896 0.034 -2.439 
ZFYVE9 NM_007324 0.043 -2.441 
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ZNF707 NR_110192 0.038 -2.455 
SGK3 NM_170709 0.038 -2.463 
VTI1A NM_145206 0.039 -2.481 
SCAPER NM_020843 0.015 -2.508 
SIRT2 NR_034146 0.012 -2.513 
RREB1 NM_001003700 0.006 -2.520 
CALU NM_001199672 0.011 -2.571 
SPECC1L NM_015330 0.000 -2.598 
FOXO3 NM_001455 0.008 -2.606 
RAD54B NM_001205262 0.032 -2.606 
SNX25 NM_031953 0.049 -2.632 
LRRC8E NM_025061 0.016 -2.633 
CTNS NM_004937 0.045 -2.636 
TRPV3 NM_145068 0.048 -2.647 
EPHA4 NM_004438 0.011 -2.649 
CPEB3 NM_001178137 0.026 -2.696 
PRDM16 NM_022114 0.009 -2.715 
WTAP NM_152858 0.027 -2.729 
KLHL7-AS1 NR_046220 0.008 -2.742 
TYRO3 NM_006293 0.047 -2.750 
CALU NM_001199671 0.015 -2.759 
DCLRE1A NM_001271816 0.001 -2.817 
OPHN1 NM_002547 0.002 -2.833 
MSANTD2 NM_001301087 0.003 -2.843 
SNX8 NM_013321 0.005 -2.872 
HK1 NM_000188 0.012 -2.874 
FAM133A NM_001171111 0.038 -2.896 
FAM69A NM_001006605 0.000 -2.906 
EIF6 NR_052023 0.023 -2.907 
SLC16A1-AS1 NR_103743 0.042 -2.911 
GFOD1 NM_018988 0.044 -2.915 
NFKBIL1 NM_001144962.3 0.044 -2.937 
ARL13B NM_001174150 0.048 -2.954 
DSN1 NM_001145318 0.011 -2.955 
NIF3L1 NM_001142355 0.040 -2.964 
ALKBH8 NM_001301010 0.039 -3.016 
ZNF492 NM_020855 0.049 -3.066 
MYO1B NM_001130158 0.028 -3.085 
NDST1 NM_001543 0.012 -3.100 
LOC101927482 NR_110226 0.034 -3.123 
ELF5 NM_001243080 0.034 -3.144 
FRMD5 NM_001286491 0.000 -3.151 
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MYBL1 NM_001294282 0.007 -3.154 
CCBL2 NM_001008661 0.043 -3.164 
FZD6 NM_001164616 0.035 -3.178 
CACHD1 NM_020925 0.043 -3.195 
PHACTR2 NM_014721 0.036 -3.210 
EHD4 NM_139265 0.004 -3.213 
AGO3 NM_024852 0.006 -3.221 
FRMD5 NR_104455 0.000 -3.222 
ARG2 NM_001172 0.036 -3.225 
DPH5 NM_015958 0.028 -3.228 
DSN1 NM_001145316 0.013 -3.250 
STK25 NM_001271977 0.001 -3.260 
DMKN NM_001035516 0.048 -3.277 
FAIM NM_018147 0.048 -3.283 
ZNF175 NM_007147 0.039 -3.297 
ZYX NM_001010972 0.032 -3.339 
SEMA7A NM_001146030 0.008 -3.341 
CCDC84 NR_104051 0.009 -3.395 
NDRG1 NM_001258432 0.042 -3.403 
FBXO32 NM_001242463 0.048 -3.419 
SAMD4A NM_001161577 0.048 -3.447 
MANBAL NM_022077 0.036 -3.472 
LOC399815 NR_027282 0.006 -3.486 
DLC1 NM_006094 0.040 -3.519 
DCTN3 NM_001281426 0.010 -3.530 
CDC7 NM_001134420 0.018 -3.530 
APBB2 NM_001166050 0.018 -3.551 
ZFPM2-AS1 NR_125796 0.045 -3.562 
RTN4 NM_207521 0.046 -3.573 
APBB2 NM_173075 0.020 -3.607 
PPP1R15A NM_014330 0.046 -3.616 
AUTS2 NM_001127231 0.049 -3.652 
PRKCQ-AS1 NR_036503 0.025 -3.677 
NDRG1 NM_006096 0.021 -3.704 
MROH1 NM_001099281 0.035 -3.735 
MYBL1 NM_001144755 0.005 -3.959 
CSTA NM_005213 0.036 -4.035 
C1S NM_201442 0.050 -4.050 
SNHG18 NR_045196 0.035 -4.107 
APBB2 NM_004307 0.033 -4.153 
KLK6 NM_001012964 0.050 -4.189 
SYNE3 NM_152592 0.002 -4.210 
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NTN1 NM_004822 0.040 -4.257 
DUXAP8 NR_122113 0.049 -4.379 
TRPV3 NM_001258205 0.042 -4.408 
FRMD5 NM_032892 0.007 -4.455 
C3orf52 NM_001171747 0.001 -4.801 
ELF5 NM_001422 0.036 -4.951 
TMEM51 NM_018022 0.024 -5.005 
LYAR NM_017816 0.030 -5.307 
MCOLN3 NM_018298 0.034 -5.443 
HMOX1 NM_002133 0.043 -5.620 
SPTLC3 NM_018327 0.019 -5.703 
LINC00341 NR_026779 0.012 -5.760 
ZNF697 NM_001080470 0.025 -5.808 
TIAM1 NM_003253 0.041 -5.840 
C3orf52 NM_024616 0.000 -5.984 
ZNF532 NM_018181 0.043 -6.143 
ABLIM3 NM_001301027 0.038 -6.236 
ZNF503 NM_032772 0.002 -6.641 
HAS2 NM_005328 0.038 -6.729 
PTPRE NM_130435 0.007 -6.864 
SMIM3 NM_032947 0.007 -7.006 
KLHL29 NM_052920 0.012 -7.095 
DLC1 NM_001164271 0.035 -7.992 
RND3 NM_005168 0.030 -8.005 
PTGS2 NM_000963 0.034 -8.353 
CRABP2 NM_001878 0.005 -8.647 
PHLDB2 NM_001134439 0.045 -8.958 
ZNF22 NM_006963 0.041 -10.130 
INHBE NM_031479 0.003 -10.215 
NUPR1 NM_012385 0.028 -10.367 
SNTB1 NM_021021 0.033 -10.501 
SERPINE1 NM_000602 0.042 -13.327 
BAMBI NM_012342 0.029 -15.399 
SLC2A3 NM_006931 0.011 -26.240 
NUPR1 NM_001042483 0.000 -36.309 
 
Pathway analysis was performed to better understand the cellular 
pathways associated with PI3K-inhibitor sensitivity. The list of differential 
expressed genes (n=617) was used to perform pathway enrichment analysis using 
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the online biological classification tool DAVID (Table 5.3). Five relevant 
pathways, ribosome, DNA replication, mismatch repair, nucleotide excision repair 
and homologous recombination were enriched. In addition to differential 
expressed genes, GO ANOVA analysis was also performed to identify the “gene 
sets” that are up- or down-regulated in the sensitive cell lines compared to the 
resistant cell lines. The top 10 “gene sets” (each representing a GO-category) with 
the highest fold change were shown in Table 5.4. The “protein tyrosine 
phosphatase activator activity” was up-regulated in the sensitive cell lines with 61 
fold change.  IGFBP3 was one the genes that is involved in the “protein tyrosine 
phosphatase activator activity”.  
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Table 5.3. Pathway prediction of the differential expressed genes (KEGG pathway). 
 
Table 5.4.  GO-ANOVA analysis of cell lines that is sensitive or resistant to PI3K inhibitor.  
 
No Term Count p-value Genes 
1 Ribosome 9 0.002 RPL18, RPL17, RPL13, RPLP0, RPS15, RPL36, RPS15A, RPL7A, RPS24 
2 DNA replication 5 0.013 RFC5, POLD4, RFC1, POLE3, POLD2 
3 Mismatch repair 4 0.020 RFC5, POLD4, RFC1, POLD2 
4 Nucleotide excision repair 5 0.026 RFC5, POLD4, RFC1, POLE3, POLD2 
5 Homologous recombination 4 0.034 POLD4, POLD2, TOP3A, RAD54B 
 
No GO Description p-value Fold-Change Description 
1 protein tyrosine phosphatase activator activity 0.001 61 Sensitive up vs Resistant 
2 insulin-like growth factor binding protein complex 0.004 24 Sensitive up vs Resistant 
3 growth factor complex 0.004 24 Sensitive up vs Resistant 
4 protein phosphatase activator activity 0.001 16 Sensitive up vs Resistant 
5 phosphatase activator activity 0.001 16 Sensitive up vs Resistant 
6 positive regulation of myoblast differentiation 0.001 15 Sensitive up vs Resistant 
7 sterol 14-demethylase activity 0.034 9 Sensitive up vs Resistant 
8 cholesterol biosynthetic process via 24,25-dihydrolanosterol 0.034 9 Sensitive up vs Resistant 
9 negative regulation of transcription by transcription factor localization 0.005 9 Sensitive up vs Resistant 




5.1.3 Validation of IGFBP3 expression in GC cell lines 
Among the shortlisted genes from the discovery set, IGFBP3 of high interest due 
to its high fold change and its involvement in insulin/insulin-like growth factor 
(IGF) signalling. IGF signalling represents one of the major upstream activators 
of the PI3K pathway (Cortes-Sempere et al., 2013). Moreover, low expression of 
IGFBP3 has been shown to be associated with resistance to Herceptin and 
cisplatin (Jerome et al., 2006; Cortes-Sempere et al., 2013). 
qRT-PCR was used to confirm the expression level of IGFBP3 in the GC 
cell lines. Figure 5.3 demonstrated a strong positive correlation (pearson 
correlation =0.85, p-value = 0.008) between qRT-PCR and RNA-sequencing.  
 
Figure 5.3. Correlation of IGFBP3 expression between RNA-seq and qRT-
PCR in the 8 GC cell lines. Relative quantification (RQ) values were obtained as 
an average from three technical replicates as relative to SNU5. Blue dots 











5.1.4 Functional validation of IGFBP3 
High expression of IGFBP3 was found to be common to all the sensitive cell 
lines. To confirm whether IGFBP3 could mediate sensitivity to PI3K inhibition, 
cell viability was assessed after combined treatment with si-IGFBP3 and PI3K 
inhibitors in YCC1 (moderate expression of IGFBP3). As shown in Figure 5.4 A, 
si-IGFBP3 treatment resulted in significant knockdown of IGFBP3 as assessed by 
western blot. A trend of decrease in drug sensitivity to PI3K inhibitors was 
observed in IGFBP3 knockdown cells although the IC50 values of GDC-0941 
(YCC1-si-Neg, IC50 =1210±155nM; YCC1-si-IGFBP3, IC50=2900±1561nM, 
p=0.135) and BKM120 (YCC1-si-Neg, IC50=2096±587nM; YCC1-si-IGFBP3, 
IC50= 3552±127nM, p=0.076) in these cells did not differ significantly from the 
parental cells.  
As this observation was found in a transient model, further investigation of 
the effect of IGFBP3 in mediating drug sensitivity in stable cells with 
overexpression of IGFBP3 was undertaken. Stable isogenic cell lines with 
overexpression of IGFBP3 were established using YCC1 (Figure 5.5A). Parental 
cells (YCC1-GFP) and cells with IGFBP3 overexpression (YCC1-IGFBP3) were 
further treated with GDC-0941 and BKM120. As shown in Figure 5.5B, YCC1-
IGFBP3 cells were more responsive to the PI3K inhibitors compared to the 
parental cells. The IC50 values of GDC-0941 (YCC1-GFP, IC50 =2609±991nM; 
YCC1-IGFBP3, IC50=780±325nM, p=0.013) and BKM120 (YCC1-GFP, IC50 
=2337±159nM; YCC1-IGFBP3, IC50=1431±257, p=0.007) were significantly 
lower in the cells with IGFBP3 overexpression than the parental cells. Taken 
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together, these results confirmed that IGFBP3 modulates drug sensitivity to PI3K 
inhibitors.  
IGFBP3 binds to IGF-1, preventing the binding of IGF-1 to its receptor 
IGF-1R. This leads to the inactivation of PI3K signalling pathway (Cortes-
Sempere et al., 2013). IGFBP3 was highly expressed in the sensitive cell lines 
compared to the resistant cell lines, it can therefore be hypothesized that high 
levels of IGFBP3 sequesters IGF-1, preventing activation of the PI3K pathway. 
This means that less PI3K inhibitors are needed to inactivate the pathway, 
rendering the cells sensitive to the PI3K drugs. To test this hypothesis, western 
blot analysis was performed to assess the phosphorylation level of IGF-1R and 
downstream of PI3K pathway in response to PI3K inhibitors. As shown in Figure 
5.5C, overexpression of IGFBP3 alone induced a decrease in pIGF-1R, pAKT and 
pS6 expression, compared to the parental cells. In the presence of 10nM and 
100nM of GDC-0941, lower expression of pAKT and pS6 were observed in 
YCC1-IGFBP3 than in YCC1-GFP. This finding indicated that less amount of 
PI3K inhibitor is needed to downregulate the PI3K/AKT pathway in cells with 
high expression of IGFBP3. Taken together, this supported our hypothesis that the 











Figure 5.4. Effect of IGFBP3 silencing on drug sensitivity. (A) Silencing 
efficiency of IGFBP3 siRNA treatment in YCC1 cells as shown by western blot. 
(B) IC50 values for GDC-0941 and BKM120 treatment of YCC1 in the presence 
of si-IGFBP3. The IC50 response curves were obtained from the average value of 
three independent experiments. Each experiment was performed in three technical 
replicates. For the IC50 response curve of si-scramble (plotted as a black line), the 
percentages of cell viability at each drug concentration were obtained by 
comparing the absorbance with the si-scramble control without drug treatment 
(DMSO treated). For the IC50 response curve of si-IGFBP3 (indicated as red line), 
the percentages of cell viability at each drug concentration were obtained by 





















Figure 5.5. Effect of IGFBP3 overexpression on drug sensitivity and PI3K 
pathway signalling. (A) Overexpression of IGFBP3 in YCC1 cells as shown by 
western blot. (B) IC50 values for GDC-0941 and BKM120 treatment of YCC1 in 
the isogenic cell lines. The IC50 response curves were obtained from the average 
value of three independent experiments. Each experiment was performed in three 
technical replicates. For the IC50 response curve of YCC1-GFP (plotted as a black 
line), the percentages of cell viability at each drug concentration were obtained by 
comparing the absorbance with the YCC1-GFP cells without drug treatment 
(DMSO treated). For the IC50 response curve of YCC1-IGFBP3 (indicated as red 
line), the percentages of cell viability at each drug concentration were obtained by 
comparing the absorbance with the YCC1-IGFBP3 cells without drug treatment 
(DMSO treated). (C) Effect of PI3K inhibition and IGFBP3 overexpression on p-
IGF1R (Tyr1161), p-ERK (Thr202/Tyr204), p-AKT (Ser473) and pS6 
(Ser235/236) protein expression in the isogenic cell lines. Representative data 







Previous in vitro studies have shown significant correlation between specific 
mutations and treatment response, however the negative predictive value of these 
mutations is often poor and not all sensitive cancers are identified by single 
mutations or single gene panels. For instance, PIK3CA mutations showed 
excellent specificity and high positive predictive value in predicting the response 
to GDC-0941, but relatively low sensitivity and a poor negative predictive value 
in predicting drug responsiveness in the breast cell line panel which were 
wildtype for PIK3CA (O'Brien et al., 2010). A number of GC cell lines without 
PIK3CA mutations were shown here to be sensitive to PI3K inhibitors, suggesting 
the need for additional biomarkers to identify subpopulations of PIK3CA wildtype 
patients who may respond to these drugs. With the exception of PIK3CA 
mutations, predictive biomarkers for PI3K inhibitors have so far not been well 
established. Therefore, a high throughput method such as RNA-sequencing was 
used here to identify novel biomarkers in PIK3CA wildtype GC cell lines in an 
unbiased manner.  
Using RNA-sequencing, IGFBP3 was one of the most significantly 
upregulated gene in the sensitive cell lines. IGFBP3 was selected for further  
functional validation due to its involvement in IGF signalling (Perks and Holly, 
2008). Interestingly, high expression of IGFBP3 was found to mediate sensitivity 
to PI3K inhibitors (Figure 5.5). Moreover, knockdown of IGFBP3 counteracted 
the effect of PI3K inhibitor in reducing the pAKT level. GC cell lines with low 
107 
 
IGFBP3 expression were resistant to PI3K inhibitor, possibly due to the need of 
higher dose to downregulate the pAKT level (see Figure 5.6). 
 
 
Figure 5.6. Schematic representation of the different status of the IGF1R/PI3K/AKT 
pathway proposed for (A) PI3K inhibitor-sensitive, or (B) -resistant cell lines 
according to their IGFBP3 expression.  
 
One of the major mechanisms of action of IGFBP3 is to bind IGF-I, thus 
preventing the interaction of IGF-I with the insulin-like growth factor-I receptor 
(IGF-IR) (Perks and Holly, 2008). The expression level of IGFBP3 has been 
correlated with sensitivity to trastuzumab in breast cancer cells (Dokmanovic et 
al., 2011). Moreover, IGFBP3 methylation status together with AKT activity, 
IGF-IR and EGFR were able to predict the response of NSCLC patients to 
cisplatin (Cortes-Sempere et al., 2013). The finding that elevated expression of 
IGFBP3 correlates with sensitivity of GC cells to PI3K inhibition may help to 
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identify clinically useful predictive biomarkers for patients with wildtype 
PIK3CA. This observation provides a basis for future clinical trials to test whether 
GC tumours with high IGFBP3 expression are more responsive to PI3K inhibitors 
than tumours with low expression. 
 Pathway enrichment analysis showed that DNA replication and mismatch 
repair were associated with sensitivity to PI3K inhibitors (Table 5.3). Resistant 
cell lines showed high expression of RFC5 and RFC1 which encode replication 
factor C subunit 5 and replication factor C subunit 1, respectively. It has been 
reported that treatment of human cancer cells with wortmannin could lead to 
reduced expression of genes of the Rad3-related protein (ATR)-checkpoint kinase 
1 (CHK1) pathway, such as RFC5, RFC2 and RFC3 (Pal et al., 2012). Moreover, 
overexpression of DNA repair genes has been shown to enhance the invasive 
behavior of tumour cells (Seedhouse et al., 2006). This also suggests that high 
expression of DNA repair genes could contribute to the drug-resistant phenotype. 
Therefore, further investigation to determine whether inhibition of RFC5 or RFC1 




6 Chapter Six:  General Discussion 
6.1 Summary of major findings  
In Chapter 3, knowledge on the frequency and associations of prominent 
candidate markers of response to PI3K inhibitors for GC and CRC was 
consolidated through comprehensive literature review and meta-analysis. The 
analyses uncovered inter-ethnic and cancer type differences in the frequencies of 
PI3K pathway aberrations. Co-occurrence analysis established that more than 
86% of GC and CRC have at least one aberration in the PI3K pathway. These 
aberrations occurred primarily in a mutually exclusive pattern. The current 
findings support the potential use of PI3K inhibitors in GC and CRC patients, 
subject to validation of the role of biomarkers in tumour samples from clinical 
trials.  
Using preclinical models in Chapter 4, several potential biomarkers for 
PI3K pathway inhibitors were identified for GC and CRC. Consistent with 
previous findings, PIK3CA mutation was found to be a biomarker for response of 
GC and CRC cell lines to PI3K inhibition. In CRC, a subtype of KRAS mutation, 
G12V, was significantly associated with higher IC50 value in response to PI3K 
inhibitor. This finding suggests that G12V could help stratify CRC patients to 
improve the efficacy to treatment with PI3K inhibitors. 
In GC cell lines with wildtype PIK3CA status, this study found for the first 
time that high expression of IGFBP3 was associated with sensitivity to PI3K 
inhibitors. This finding is important as it could help to identify PIK3CA wildtype 
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patients who will be responsive to PI3K inhibitors. However, studies on tissue 
samples from clinical trials are again required to confirm this observation. The 
current results point to a potential combination therapy in GC patients involving 
PI3K inhibitors and IGF-1R inhibitor. It will be interesting to further investigate 
the expression patterns of IGFBP3 in GC patients to determine whether they can 
be confirmed as biomarkers for PI3K inhibitor therapy in GC.  
 
6.2 Recent developments in the identification of biomarkers for PI3K 
inhibitors 
6.2.1 PIK3CA mutation 
As mentioned previously, the association between PIK3CA mutations and the 
sensitivity to PI3K inhibitors was inconsistent as shown in several studies.  A 
possible reason for these discrepancies is that different cell types have different 
genetic determinants to drug sensitivity. For example, the BRAF mutation hotspot 
V600E is a strong predictive biomarker for response to vemurafenib in melanoma, 
but not for the response of CRC patients to this BRAF inhibitor (Prahallad et al., 
2012) .  
To my knowledge, this is the largest panel of GC cancer cell lines 
screened to date and highlights the potential use of PIK3CA mutation as pre-
selection criteria in clinical trials. The meta-analyses indicated the frequencies of 
mutations in PIK3CA exons 9 and 20 in GC differ significantly between East 
Asians and Caucasians (Chapter 3). This suggests that the response rate of East 
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Asian patients might be lower than Caucasian patients to PI3K inhibitors. 
Nevertheless, the full clinical potential of this biomarker remains to be confirmed 
through clinical trials.  
 
6.2.2 High expression of IGFBP3 
High expression of IGFBP3 was associated with higher sensitivity to PI3K 
inhibitors in GC cell lines with PIK3CA wildtype (Chapter 5). IGFBP3 binds to 
circulating IGF-I, thus preventing activation of the IGF signaling pathway 
(Phillips et al., 1998). Recently, overexpression of IGF-IR was identified as one 
of the major mediators of resistance in four cancer cell lines with acquired 
resistance to ZSTK474, a PI3K inhibitor (Isoyama et al., 2012). In line with the 
present study, this finding implicates the IGF signaling pathway in mediating 
sensitivity to PI3K inhibitors. Aberrant DNA methylation and histone acetylation 
have been shown to play an important role in the silencing of IGFBP3 expression 
in several human cancers, including GC and CRC (Tomii et al., 2007). IGFBP3 
expression is significantly up-regulated by 5-aza-CdR treatment in gastric cancer 
cell lines (Yamashita et al., 2006), providing further evidence that IGFBP3 
expression is regulated by DNA methylation. Moreover, a common 
polymorphism in the IGFBP3 promoter region has been associated with the level 
of circulating IGFBP3 in breast cancer (Schernhammer et al., 2003). Therefore, it 
will be interesting to investigate whether tumour methylation of IGFBP3 or the 
genetic polymorphism have predictive value as markers of response to PI3K 
inhibitors in GC.  
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6.3 In-vitro efficacy of different PI3K inhibitors 
Fingerprints are defined as the patterns of differential drug efficacy across a panel 
of cell lines and have been found to reflect mechanisms of drug action (Dan et al., 
2010). By analyzing the fingerprints of different PI3K inhibitors across the 8 cell 
lines, GDC-0941 and BSP-A were found to be highly correlated (Pairwise 
Pearson correlation coefficient=0.88), suggesting a close similarity in the 
molecular mechanisms of action between each pair of compounds. It is probable 
that both GDC-0941 and BSP-A are p110α and p110δ isoform-specific inhibitors.  
In Elkabets et al.’s study, BYL719 was tested in a panel of 20 PIK3CA-
mutant and 5 PIK3CA-wild-type cell lines. BYL719 is known to have high 
potency in cell lines with PIK3CA mutation (Elkabets et al., 2013). The majority 
of cell lines had low IC50 values (~1µM) because these sensitive cells contained 
PIK3CA mutation. However, the 8 GC cell lines that were tested with BYL719 
were all PIK3CA-wildtype cells. According to the Elkabets et al. study, 4 of 
PIK3CA-wildtype cell lines (80%) showed IC50 values >10µM in response to 
BYL719. This is in line with the current finding, in which 6 out of 8 (75%) 
PIK3CA-wildtype cell lines had IC50 values >10µM in response to BYL719.  
A detailed analysis of the fingerprint of BKM120 with those of other PI3K 
inhibitors showed a relatively poor correlation, suggesting that perhaps BKM120 
has a similar efficacy in inhibiting all four p110 subunits or it could mean that 
these are off-target effects. Previous published data showed that the IC50 values of 
BKM120 ranged from approximately 800 to 3000nM in a panel of 11 GC cell 
lines (Park et al., 2012), and this is consistent with my finding. 
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6.4 Limitations of this study and future directions 
The meta-analyses indicated that East Asians and Caucasians differ significantly 
in terms of the frequencies of PIK3CA mutation, PTEN deletion and PTEN loss in 
GC, and of PTEN loss in CRC. However, considerable heterogeneity was 
observed for all aberrations, with the exception of PIK3CA mutations in both GC 
and CRC. Comparison of the present study cohort (East Asian) with tumour 
samples from a Caucasian cohort should provide valuable information regarding 
the possibility of ethnic-specific aberrations in the PI3K pathway.  
In the current study, PIK3CA amplification was found to be one of the 
major genetic aberrations in GC and the frequency was consistent with previous 
reports on Asian patients (Byun et al., 2003; Shi et al., 2012). In contrast, Kiyose 
et al. reported a frequency of only 3% for PIK3CA amplification in Asian GC 
patients (Kiyose et al., 2012). It should be noted that the assay methods used in 
my study and in the Byun et al. and Shi et al. studies were PCR-based, whereas 
the method used by Kiyose was fluorescent in situ hybridization (FISH)-based. 
Thus, the large discrepancy in reported frequencies between different could be 
due to different techniques and thresholds. It appears that different assay methods 
such as FISH and qPCR can lead to different amplification frequencies even in 
the same patient cohort (Zaczek et al., 2012). PIK3CA amplification has been 
used as inclusion criteria for the p110α-specific inhibitor BYL719 in advanced 
stage GC (NCT01613950), hence accurate determination of PIK3CA 
amplification in GC patients is essential. It will be important to assess the 
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concordance between FISH and qPCR in future studies so that the best method 
can be used to routinely evaluate PIK3CA amplification. 
Two major PI3K aberration subtypes were identified in clinical samples of 
GC (PTEN loss alone and PIK3CA amplification/PTEN loss) and CRC (PTEN 
loss alone and PTEN loss/high pAKT) (Figure 3.3). However, the effects of PI3K 
inhibitors in these subtypes have not been addressed using preclinical models. 
This will be an interesting area for future investigation with PI3K inhibitors.   
BSP-A and BSP-B are proprietary drugs provided by Bayer 
pharmaceuticals and their in vitro kinase activities are not publicly available. The 
sensitivity profile between the two drugs was not identical. A possible explanation 
for this could be differences in the mechanism of action. For instance, 
GSK2636771 (p110β-isoform specific inhibitor) is currently being tested in a 
clinical trial of PTEN-deficient malignancies following observations in preclinical 
models that suggested PTEN deficient cancers may depend on signaling via 
p110β rather than p110α (Jia et al., 2008; Wee et al., 2008). Therefore, 
knowledge of the in vitro kinase activities of these PI3K inhibitors may help to 
shed more light on the differences between BSP-A and BSP-B with respect to 
their regulation of GC cell growth. Unfortunate, this information was unavailable 
due to confidentially issues. 
High expression of IGFBP3 was found in this study to be associated with 
higher sensitivity to PI3K inhibitors. Knockdown of IGFBP3 using siRNA was 
used to confirm the role of IGFBP3 in mediating drug sensitivity in YCC1 . I 
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hypothesize that overexpression of IGFBP3 in resistant cell lines can reverse the 
effect of PI3K inhibition from resistant to sensitive. Experiments such as the 
overexpression of IGFBP3 in resistant cell lines could be used to further 
investigate this potential mechanism of resistance to PI3K inhibitors. This 
provides a rationale for combining IGF-1R and PI3K inhibitors for the treatment 
of GC. However, this combination effect still remains to be elucidated. 
 
6.5 Future perspectives 
Based on previous studies, the majority of PIK3CA mutations occur in exon 9 and 
exon 20 which encodes the helical and kinase domain, respectively (Kong et al., 
2014). A meta-analysis demonstrated a higher frequency of PIK3CA mutation in 
exons 9 and 20 were found in Caucasians rather than in East Asian populations. 
Further study is necessary to validate this finding independently.. Apart from hot 
spot mutations, whole exome sequencing analysis has also identified other non-
hot spot PIK3CA mutations in GC (Cancer Genome Atlas Research, 2014). Only 
hot spot PIK3CA mutations were analyzed in this study and therefore, it will be 
interesting to know if other PIK3CA mutations can be used to predict the 
sensitivity of PI3K inhibitors. The current findings from this study suggest that 
high expression of IGFBP3 is a potential biomarker for the efficacy of the use of 
PI3K inhibitors in PIK3CA wildtype cell lines , however, this finding should be 
further validated in clinical samples. Furthermore, it would also be worth 
exploring if overexpression of IGFBP3 is the result of copy number aberration. It 
is important to understand the relationship between PIK3CA mutation and 
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overexpression of IGFBP3 in GC patients because it would assist in prioritization 
during biomarker screening.  
 Overexpression of IGFBP3 increased the sensitivity of GC cells to PI3K 
inhibitor and decreased the activity of IGF-/PI3K/AKT signaling. However, it will 
also be interesting to investigate if the extracellular priming of IGF-1 or 
knockdown of IGFBP3 in the YCC1-IGFBP3 (IGFBP overexpression) cells will 
reverse the effects of IGFBP3 on drug sensitivity.  A previous study has reported 
that exogenous IGF-1 stimulates the growth of SNU cells, irrespective of the 
status of IGFBP3 expression. These results strongly suggest that basal levels of 
endogenous IGFBP3 may inhibit the growth of gastric cancer either in an IGF-
dependent or IGF-independent manner (Yi et al., 2001). IGFBP3 overexpression 
and its association with decreased activity of IGF/PI3K/AKT signaling suggests 
the increase in drug sensitivity could be due to IGF-dependent mechanism (Figure 
5.4). However, whether the IGF-independent mechanism contributes to regulation 
of drug sensitivity remains to be determined. Therefore, further studies are needed 
to determine the specific mechanism of action of IGFBP3 in GC.  
To date, the use of single agent PI3K inhibitor in therapy has not been 
promising and this may be partially explained by a narrow therapeutic window, 
particularly with pan-PI3K inhibitors (Fruman and Rommel, 2014). The adverse 
events of PI3K inhibitors also preclude the consistent delivery of doses necessary 
for adequate pathway inhibition. However, combination strategies may help to 
reduce the toxicity (Fruman and Rommel, 2014). In the present study, knockdown 
of IGFBP3 was found to increase resistance to PI3K inhibitors in GC cell lines 
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(Figure 5.4). It is therefore plausible that combining IGF signalling pathway 
inhibitors and PI3K inhibitors may increase the proportion of cancers that benefit 
from PI3K inhibitors and delay the development of resistance in cancers that are 
initially responsive. PI3K inhibitors will eventually play an important role in 
clinical practice across multiple tumour types once more clinical trials data is 
collected. Future studies will likely rely heavily on patient’s selection strategies 
and combination approaches to determine how to maximize the efficacy of these 
agents in the treatment of patients with cancer. 
 
6.6 Conclusions  
This study has consolidated information in the literature on the frequency of 
different PI3K pathway aberrations. It has also revealed ethnic differences and co-
occurrence patterns for PI3K pathway aberration in GC and CRC. The results 
suggest that PIK3CA and KRAS (G12V) mutations could be used as biomarkers 
for PI3K inhibitors in GC and CRC. PIK3CA wildtype tumours, high expression 
of IGFBP3 could be a biomarker for the selection of GC patients who respond to 
PI3K inhibitors. Additional mechanistic studies are required to investigate the 
functional significance of IGFBP3 in mediating resistance to PI3K inhibitors. A 
better understanding of the known and candidate biomarkers described in this 
study could eventually lead to improved stratification of GC and CRC patients for 
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Appendix Figure 1. cDNA quality analysis using Agilent Bioanalyzer.  cDNA 
was converted from rRNA-depleted RNA using ScriptSeq
TM
 v2 mRNA-Seq 
Library Preparation Kit. The Bioanalyzer showed optimal cDNA fragmentation in 
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Appendix Figure 2. Per base sequence quality of 8 GC cell lines (RNA-
sequencing). The y-axis on the graph shows the quality scores. The higher the 
score the better the base call. The background of the graph divides the y axis into 
very good quality calls (green), calls of reasonable quality (orange), and calls of 
poor quality (red).The central red line is the median value. The yellow box 
represents the inter-quartile range (25-75%). The upper and lower whiskers 






Appendix Table 1. Total sequences and aligned reads obtained from RNA-
sequencing.  
 
Cell lines Total reads Aligned reads 
HS746T 57528536 54000777 
Kato3 79409139 63896235 
MKN28 103674181 74139979 
NUGC3 61965021 43856415 
NUGC4 82924921 59710746 
SNU5 89097623 66913289 
YCC1 83076193 40317541 
YCC11 81886491 73318968 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
